Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus by United States Public Health Service.




U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service









The MMWR series of publications is published by the Epidemiology Program Office,
Centers for Disease Control and Prevention (CDC), Public Health Service, U.S. Depart-
ment of Health and Human Services, Atlanta, GA 30333.
Centers for Disease Control and Prevention.......................... David Satcher, M.D., Ph.D.
Director 
The material in this report was prepared for publication by:
 National Center for Infectious Diseases.................................. James M. Hughes, M.D.
Director 
  Division of AIDS, STD, and TB Laboratory Research..............Harold W. Jaffe, M.D.
Director 
 National Center for HIV, STD, and TB Prevention ......... Helene D. Gayle, M.D., M.P.H.
Director 
  Division of HIV/AIDS Prevention, Surveillance,
   and Epidemiology................................................................Kevin M. DeCock, M.D.
Director  
The production of this report as an MMWR serial publication was coordinated in:
 Epidemiology Program Office.................................... Stephen B. Thacker, M.D., M.Sc.
Director 
Richard A. Goodman, M.D., M.P.H.
Editor, MMWR Series 
  Office of Scientific and Health Communications (proposed)
   Recommendations and Reports................................... Suzanne M. Hewitt, M.P.A.
Managing Editor 
Nadine W. Martin
Ava W. Navin, M.A.
Project Editors 
  Morie M. Higgins
Peter M. Jenkins
Visual Information Specialists 
SUGGESTED CITATION
Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the
prevention of opportunistic infections in persons infected with human immuno-
deficiency virus. MMWR 1997;46(No. RR-12):[inclusive page numbers].
Use of trade names and commercial sources is for identification only and does not




How to Use the Information in This Report.................................................2







Disseminated Infection with Mycobacterium avium Complex...............12
Bacterial Respiratory Infections ..................................................................13
Bacterial Enteric Infections ..........................................................................15






Herpes Simplex Virus Disease ....................................................................24
Varicella-Zoster Virus Infection ...................................................................25
Human Papillomavirus Infection.................................................................25
Immunologic Categories for HIV-infected Children .........................................27
Drug Regimens for Adults and Adolescents ....................................................28
Drug Regimens for Children ..............................................................................32
Immunization Schedule for HIV-Infected Children ...................................34
Prevention of Exposure Recommendations.....................................................38
Costs of Drugs and Vaccines .............................................................................44
References...........................................................................................................45
Copies can be purchased from Superintendent of Documents, U.S. Government
Printing Office, Washington, DC 20402-9325. Telephone: (202) 512-1800.
Single copies of this document are available from the Centers for Disease Control
and Prevention, National AIDS Clearinghouse, P.O. Box 6003, Rockville, MD 20849-
6003. Telephone: (800) 458-5231.
Vol. 46 / No. RR-12 MMWR i
The following CDC staff member prepared this report:
Jonathan E. Kaplan, M.D.
National Center for Infectious Diseases
Division of AIDS, STD, and TB Laboratory Research
and
National Center for HIV, STD, and TB Prevention
Division of HIV/AIDS Prevention, Surveillance, and Epidemiology
in collaboration with
Henry Masur, M.D.
National Institutes of Health
King K. Holmes, M.D., Ph.D.
University of Washington
USPHS/IDSA Prevention of Opportunistic Infections
Working Group
ii MMWR June 27, 1997
Members of the USPHS/IDSA Prevention of Opportunistic Infections Working Group
The working group was chaired by Henry Masur, National Institutes of Health,
Bethesda, MD; Jonathan E. Kaplan, Centers for Disease Control and Prevention,
Atlanta; and King K. Holmes, University of Washington, Seattle.
Members of the group included Donald Armstrong (Memorial-Sloan Kettering
Cancer Center, New York); A. Cornelius Baker (National Association of Persons with
AIDS, Washington, DC); David Barr (Gay Men’s Health Crisis, Washington, DC);
Constance Benson (Rush Medical College, Chicago); Carol Brosgart (East Bay AIDS
Center, Berkeley, CA); Richard Chaisson (The Johns Hopkins University, Baltimore);
Ellen Cooper (National Institutes of Health, Bethesda, MD); Clyde Crumpacker (Beth
Israel Hospital, Boston); Catherine Decker (National Naval Medical Center, Bethesda,
MD); Larry Drew (Mt. Zion Medical Center of UCSF, San Francisco); Robert Eisinger
(National Institutes of Health, Bethesda, MD); Wafaa El-Sadr (Harlem Hospital Center,
New York); Kenneth Freedberg (Boston Medical Center, Boston); Mark Goldberger
(Food and Drug Administration, Rockville, MD); Fred Gordin (Veterans Administration
Medical Center, Washington, DC); Wayne Greaves (Howard University Hospital, Wash-
ington, DC); Peter Gross (Hackensack Medical Center, Hackensack, NJ); Richard Hafner
(National Institutes of Health, Bethesda, MD); Diane Havlir (University of California at
San Diego, La Jolla, CA); Robert Horsburgh (Emory University, Atlanta); Douglas Jabs
(The Johns Hopkins University, Baltimore); Mari Kitahata (University of Washington,
Seattle); Joseph Kovacs (National Institutes of Health, Bethesda, MD); William
Martone (National Foundation for Infectious Disease, Bethesda, MD); Douglas Mayers
(Naval Medical Research Institute, Bethesda, MD); David Melnick (Kaiser Permanente,
Springfield, VA); Lynne Mofenson (National Institutes of Health, Bethesda, MD);
James Neaton (University of Minnesota, Minneapolis); Charles Nelson (National
Minority AIDS Council, Washington, DC); Edward Oldfield (Eastern Virginia Medical
School, Norfolk, VA); John Phair (Northwestern University Medical School, Chicago);
Michael Polis (National Institutes of Health, Bethesda, MD); Bruce Polsky (Memorial
Sloan-Kettering Cancer Center, New York); William Powderly (Washington University,
St. Louis, MO); David Rimland (Veterans Administration Medical Center, Atlanta);
Elaine Sloand (National Institutes of Health, Bethesda, MD); Liza Solomon (Maryland
Department of Health and Mental Hygiene, Baltimore); Stephen Spector (University of
California at San Diego, La Jolla, CA); Rhoda Sperling (Mt. Sinai Medical Center, New
York); Carol Braun Trapnell (Food and Drug Administration, Rockville, MD); Russell
Van Dyke (Tulane University School of Medicine, New Orleans); Richard Whitley
(University of Alabama, Birmingham, AL); and Tom Wright (Columbia University
College of Physicians and Surgeons, New York). Participants from the Centers for Dis-
ease Control and Prevention, Atlanta, included Ermias Belay, Jay C. Butler, Kenneth
G. Castro, Clare Dykewicz, Brian R. Edlin, Tedd Ellerbrock, Rana A. Hajjeh, Harold
W. Jaffe, Dennis Juranek, Michael McNeil, Bess Miller, Philip E. Pellett, William
Reeves, W. William Schluter, Richard A. Spiegel, John A. Stewart, Barbara Styrt,
Suzanne D. Vernon, and John Ward.
Vol. 46 / No. RR-12 MMWR iii
iv MMWR June 27, 1997
1997 USPHS/IDSA Guidelines





In 1994, the U.S. Public Health Service (USPHS) and the Infectious Diseases Society
of America (IDSA) recognized that, although strategies were available to reduce the
frequency of opportunistic infections in patients who have human immunodeficiency
virus (HIV) infection, information regarding prevention of both exposure and disease
often was published in journals not regularly reviewed by health-care providers. In
response, USPHS/IDSA developed comprehensive guidelines for health-care provid-
ers and patients that consolidated information pertaining to the prevention of
opportunistic infections in persons infected with HIV. The resulting USPHS/IDSA
guidelines were published in 1995 in the MMWR, Clinical Infectious Diseases, and the
Annals of Internal Medicine, with an accompanying editorial in the Journal of the
American Medical Association (1–4 ). The response to the 1995 guidelines (e.g., the
many requests for reprints and observations from health-care providers) suggests
that they have served as a valuable reference against which local policies regarding
prevention of opportunistic infections could be compared. Because recommendations
were rated on the basis of the strength of the evidence supporting them, readers were
able to assess for themselves to which areas adherence was most important (5 ).
In the United States, opportunistic infections continue to produce morbidity and
mortality among the estimated 650,000–900,000 persons who are infected with HIV,
especially among the estimated 200,000–250,000 persons who are severely immuno-
suppressed (i.e., persons who have a CD4+ T-lymphocyte count of <200 cells/µL)
(6-10 ). However, surveillance data indicate that the incidence of opportunistic infec-
tions has been changing in the United States. In HIV-infected men who have sex with
men, Pneumocystis carinii pneumonia (PCP), toxoplasmic encephalitis, fungal infec-
tions, and disseminated Mycobacterium avium complex (MAC) disease have
decreased in incidence (9 ). Prophylactic regimens against opportunistic pathogens
and more potent antiretroviral drugs appear to be important factors influencing this
decline in incidence. However, these decreases have not been observed among HIV-
infected injecting-drug users, suggesting that more emphasis should be placed on
providing currently recommended chemoprophylactic agents to all persons who have
HIV infection and who meet appropriate criteria for prophylaxis for opportunistic in-
fections. The surveillance data also indicate that the incidence of some opportunistic
infections is not decreasing among either men who have sex with men or injecting-
drug users, indicating that preventive strategies need to be developed and applied to
a wider spectrum of opportunistic infections.
Because much new data concerning the prevention of opportunistic disease have
emerged since 1994, the USPHS and the IDSA reconvened a working group on
November 7-8, 1996, to determine which recommendations needed to be changed.
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Participants included representatives from federal agencies, universities, and profes-
sional societies, as well as community health-care providers and patient advocates.
Most attention was focused on recent data related to chemoprophylaxis against dis-
seminated MAC disease, cytomegalovirus (CMV), and fungal infections and to
immunization against Streptococcus pneumoniae. However, data concerning all the
common acquired immunodeficiency syndrome (AIDS)-associated pathogens were
reviewed, as appropriate. Factors considered in revising guidelines included:
• Incidence of disease
• Severity of disease in terms of morbidity and mortality
• Level of immunosuppression at which disease is most likely to occur
• Feasibility, efficacy, and cost of preventive measures
• Impact of intervention on quality of life
• Toxicities, drug interactions, and the potential for drug resistance to develop
Consultants reviewed published manuscripts, abstracts, and material presented at
professional meetings. However, guidelines were revised only if complete manu-
scripts providing data were available for review. A review of the data that served as
the basis for the revisions, as well as the additional information discussed at the meet-
ing but not deemed appropriate to justify a revision of the recommendations, will be
published elsewhere (11 ).
The guidelines developed by the USPHS/IDSA working group were made available
for public comment by an announcement in the Federal Register and in the MMWR,
and the final document was approved by the USPHS and the IDSA, as well as by the
American College of Physicians, the American Academy of Pediatrics, the Infectious
Diseases Society of Obstetrics and Gynecology, the Society of Healthcare Epidemiolo-
gists of America, and the National Foundation for Infectious Diseases.
How to Use the Information in This Report
This report presents disease-specific recommendations for prevention of a) expo-
sure to the opportunistic pathogen, b) first episode of disease, and c) disease
recurrence, accompanied by a description of the rating system (see Box), categories of
immunosuppression in HIV-infected children (Table 1), drugs and doses for prevention
of first episode of disease and disease recurrence in adults (Tables 2A and 2B) and
children (Table 3A, Figure, and Table 3B), recommendations for prevention of expo-
sure to opportunistic pathogens (Table 4), and costs of commonly used prophylactic
drugs and vaccines (Table 5). Because of their length and complexity, the tables and
figure have been placed at the end of the text, preceding the references. 
Recommendations are rated by a revised version of the IDSA rating system
(see Box) (5 ). In this system, a letter rating (letters A through E) signifies the strength
of the recommendation; a Roman numeral (Roman numerals I through III) indicates
the quality of the evidence supporting that recommendation.
In the original guidelines (1–3 ), prophylaxis against PCP, toxoplasmic encephalitis,
and tuberculosis for HIV-infected persons meeting appropriate criteria was rated A.
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In this updated report, the most important changes are a) the elevation from a B to an
A rating of prophylaxis against disseminated MAC disease for both adults and
children who have low CD4+ T-lymphocycte counts (Tables 2A and 3A), b) the recom-
mendation that clarithromycin or azithromycin be considered first-choice drugs for
MAC prophylaxis, with rifabutin as an alternative, and c) the elevation from a B to an
A rating of vaccination against S. pneumoniae in adults with a CD4+ T-lymphocyte
count ≥200 cells/µL. The immunization schedule for HIV-infected children also has
been revised to demonstrate the similarities and the differences between this sched-
ule and that for immunocompetent children (Figure). Prophylaxis against first
episodes of CMV and fungal diseases remains optional, as in the earlier edition of the
guidelines. 
Although not included in the disease-specific recommendations, an important is-
sue in opportunistic-infection prophylaxis is whether to offer or continue prophylaxis
on the basis of the lowest CD4+ T-lymphocyte count or of a more recent count that has
been elevated as a result of antiretroviral therapy. This issue is particularly pertinent
because of the administration of potent drug combinations that include protease in-
hibitors, which may increase CD4+ counts by 100–250 cells/µL. It is currently unknown
whether such increases in CD4+ counts provide anti-infective protection comparable
with that afforded to patients whose counts never declined below the current level.
Until data assessing these risks are available, most experts recommend that prophy-
laxis be initiated or continued on the basis of the lowest CD4+ count.
This report is oriented toward prevention of specific opportunistic infections in HIV-
infected persons. Integrated approaches to preventing opportunistic infections in
HIV-infected persons, as well as other aspects of HIV care, have been published else-
where (12,13 ). Recommendations for antiretroviral therapy, which is designed to
prevent immunologic deterioration and delay the need for many of the chemoprophy-
lactic strategies described in this document, are also addressed separately (14 ).




(1) Although some authorities recommend that HIV-infected persons at risk for
P. carinii pneumonia (PCP) not share a hospital room with a patient who has PCP, data
are insufficient to support this recommendation as standard practice (CIII).
Prevention of Disease
(2) Adults and adolescents who have HIV infection (including those who are preg-
nant) should be administered chemoprophylaxis against PCP if they have a CD4+
Rating system for strength of recommendation and quality of evidence supporting
the recommendation*
Category Definition
Categories Reflecting the Strength of Each Recommendation
A Both strong evidence for efficacy and substantial clinical benefit support
recommendation for use. Should always be offered.
B Moderate evidence for efficacy—or strong evidence for efficacy, but only
limited clinical benefit—supports recommendation for use. Should
generally be offered.
C Evidence for efficacy is insufficient to support a recommendation for or
against use, or evidence for efficacy may not outweigh adverse
consequences (e.g., toxicity, drug interactions, or cost of the
chemoprophylaxis or alternative approaches). Optional.
D Moderate evidence for lack of efficacy or for adverse outcome supports
a recommendation against use. Should generally not be offered.
E Good evidence for lack of efficacy or for adverse outcome supports a
recommendation against use. Should never be offered.
Categories Reflecting Quality of Evidence Supporting the Recommendation
I Evidence from at least one properly randomized, controlled trial
II Evidence from at least one well-designed clinical trial without
randomization, from cohort or case-controlled analytic studies
(preferably from more than one center), or from multiple time-series
studies or dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities based on clinical
experience, descriptive studies, or reports of expert committees
*Modified from (5 ).
CATEGORIES REFLECTING STRENGTH AND QUALITY OF
EVIDENCE 
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T-lymphocyte count of <200/µL (AI), unexplained fever (>100 F [37.7 C]) for ≥2 weeks
(AII), or a history of oropharyngeal candidiasis (AII).
Trimethoprim-sulfamethoxazole (TMP-SMZ) is the preferred prophylactic agent
(AI). One double-strength tablet/day is the preferred regimen (AI). However, one
single-strength tablet/day also appears to be highly effective and may be better toler-
ated (AI). TMP-SMZ may confer cross-protection against toxoplasmosis (AII) and
many bacterial infections (AII). For patients who have an adverse reaction that is not
life-threatening, treatment with TMP-SMZ should be continued if clinically feasible;
for those who have discontinued such therapy, its reinstitution should be strongly
considered (AII). Whether it is best to reintroduce the drug at the original dose or at a
lower and gradually increasing dose or to try a desensitization regimen is unknown.
If TMP-SMZ cannot be tolerated, alternative prophylactic regimens include
dapsone (BI), dapsone plus pyrimethamine plus leucovorin (BI), and aerosolized
pentamidine administered by the Respirgard IITM nebulizer (Marquest, Englewood,
CO) (BI). Regimens that include dapsone plus pyrimethamine also are protective
against toxoplasmosis (AI) but not against most bacterial infections. Because data re-
garding their efficacy for PCP prophylaxis are insufficient for a firm recommendation,
the following regimens generally cannot be recommended for this purpose: aero-
solized pentamidine administered by other nebulization devices currently available
in the United States, intermittently administered parenteral pentamidine, oral
pyrimethamine/sulfadoxine, oral clindamycin plus primaquine, oral atovaquone, and
intravenous trimetrexate. However, the use of these agents may be considered in
unusual situations in which the recommended agents cannot be administered (CIII).
Prevention of Recurrence
(3) Adults and adolescents who have a history of PCP should be administered
chemoprophylaxis with the regimens indicated above to prevent recurrence (AI).
Notes
Pediatric Notes
(4) Children born to HIV-infected mothers should be administered prophylaxis with
TMP-SMZ beginning at 4–6 weeks of age (15 ) (AII). Prophylaxis should be discontin-
ued for children who are subsequently found not to be infected with HIV. HIV-infected
children and children whose infection status remains unknown should continue to
receive prophylaxis for the first year of life. The need for subsequent prophylaxis
should be determined on the basis of age-specific CD4+ T-lymphocyte count thresh-
olds (15,16, Table 1) (AII).
(5) Children who have a history of PCP should be administered lifelong chemo-
prophylaxis to prevent recurrence (AI).
Note Regarding Pregnancy
6) Chemoprophylaxis for PCP should be administered to pregnant women as well
as to other adults and adolescents (AIII). TMP-SMZ is the recommended prophylactic
agent. Because of theoretical concerns regarding possible teratogenicity associated
with drug exposures during the first trimester, providers may choose to withhold
prophylaxis with TMP-SMZ during the first trimester. In such cases, aerosolized
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pentamidine may be considered because of its lack of systemic absorption and the
resultant lack of exposure of the developing embryo to the drug (CIII).
Toxoplasmic Encephalitis
Prevention of Exposure
(1) HIV-infected persons should be tested for IgG antibody to Toxoplasma soon
after the diagnosis of HIV infection to detect latent infection with Toxoplasma gondii
(BIII).
(2) All HIV-infected persons, but particularly those who lack IgG antibody to
Toxoplasma, should be counseled about the various sources of toxoplasmic infection.
They should be advised not to eat raw or undercooked meat, particularly undercooked
pork, lamb, or venison (BIII). Specifically, meat should be cooked to an internal tem-
perature of 150 F (65.5 C); meat cooked until it is no longer pink inside generally has
an internal temperature of 165 F (73.8 C) and therefore satisfies this requirement. HIV-
infected persons should wash their hands after contact with raw meat and after
gardening or other contact with soil; in addition, they should wash fruits and vegeta-
bles well before eating them raw (BIII). If the patient owns a cat, the litter box should
be changed daily, preferably by an HIV-negative, nonpregnant person; alternatively,
the patient should wash the hands thoroughly after changing the litter box (BIII).
Patients should be encouraged to keep their cats inside and not to adopt or handle
stray cats (BIII). Cats should be fed only canned or dried commercial food or well-
cooked table food, not raw or undercooked meats (BIII). Patients need not be advised
to part with their cats or to have their cats tested for toxoplasmosis (EII).
Prevention of Disease
(3) Toxoplasma-seropositive patients who have a CD4+ T-lymphocyte count of
<100/µL should be administered prophylaxis against toxoplasmic encephalitis (TE)
(AII). The doses of TMP-SMZ recommended for PCP prophylaxis appear to be effective
against TE as well (AII). If patients cannot tolerate TMP-SMZ, the regimens including
dapsone plus pyrimethamine that are recommended for PCP prophylaxis provide pro-
tection against TE (AI). Prophylactic monotherapy with dapsone, pyrimethamine,
azithromycin, clarithromycin, or atovaquone cannot be recommended on the basis of
current data (DII). Aerosolized pentamidine does not afford protection against TE (EI).
(4) Toxoplasma-seronegative persons who are not taking a PCP prophylactic regi-
men known to be active against TE should be retested for IgG antibody to Toxoplasma
when their CD4+ T-lymphocyte count declines below 100/µL to determine whether
they have seroconverted and are therefore at risk for TE (CIII). Patients who have sero-
converted should be administered prophylaxis for TE as described above (AII).
Prevention of Recurrence
(5) Patients who have had TE should be administered lifelong suppressive therapy
with drugs active against Toxoplasma to prevent relapse (AI). The combination
of pyrimethamine plus sulfadiazine and leucovorin is highly effective for this purpose
(AI). A commonly used regimen for patients who cannot tolerate sulfa drugs is
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pyrimethamine plus clindamycin (BI); however, only the combination of pyrimeth-
amine plus sulfadiazine appears to provide protection against PCP as well (AII).
Notes
Pediatric Note
(6) TMP/SMZ, when administered for PCP prophylaxis, also provides prophylaxis
against toxoplasmosis. Children aged >12 months who qualify for PCP prophylaxis
and who are receiving an agent other than TMP/SMZ should have serologic testing for
Toxoplasma antibody, because alternative drugs for PCP prophylaxis may not be
effective against Toxoplasma (BIII). If seropositive for Toxoplasma, children should
be administered prophylaxis for both PCP and toxoplasmosis (i.e, dapsone plus
pyrimethamine)(BIII).
Notes Regarding Pregnancy
(7) TMP-SMZ can be administered for prophylaxis against TE as described for
PCP (AIII). However, because of the low incidence of TE during pregnancy and the
possible risk associated with pyrimethamine treatment, chemoprophylaxis with
pyrimethamine-containing regimens can reasonably be deferred until after pregnancy
(CIII). For prophylaxis against recurrent TE, the health-care provider and clinician
should be well informed about the benefit of lifelong therapy and the concerns about
teratogenicity of pyrimethamine. Most clinicians favor lifelong therapy for the mother,
given the high likelihood that disease will recur promptly if therapy is stopped (AIII).
(8) In rare cases, HIV-infected pregnant women who have serologic evidence of
remote toxoplasmic infection have transmitted Toxoplasma to the fetus in utero. Preg-
nant HIV-infected women who have evidence of primary toxoplasmic infection
or active toxoplasmosis (including TE) should be evaluated and managed during
pregnancy in consultation with appropriate specialists (CIII). Infants born to women
who have serologic evidence of infections with HIV and Toxoplasma should be evalu-
ated for congenital toxoplasmosis (CIII).
Cryptosporidiosis
Prevention of Exposure
(1) HIV-infected persons should be educated and counseled about the many ways
that Cryptosporidium can be transmitted. Modes of transmission include contact with
infected adults and diaper-aged children, contact with infected animals, drinking
contaminated water, and contact with contaminated water during recreational activi-
ties (BIII).
(2) HIV-infected persons should avoid contact with human and animal feces. They
should be advised to wash their hands after contact with human feces (e.g., during
diaper changing), after handling pets, and after gardening or other contact with soil.
HIV-infected persons should avoid sexual practices that may result in oral exposure to
feces (e.g., oral-anal intercourse) (BIII).
(3) HIV-infected persons should be advised that newborn and very young pets may
pose a small risk of cryptosporidial infection, but they should not be advised to de-
stroy or give away healthy pets. Persons contemplating the acquisition of a new pet
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should avoid bringing any animal that has diarrhea into their households, should
avoid purchasing a dog or cat aged <6 months and should not adopt stray pets. HIV-
infected persons who wish to assume the small risk of acquiring a puppy or kitten
aged <6 months should request that their veterinarian examine the animal’s stool for
Cryptosporidium before they have contact with the animal (BIII).
(4) HIV-infected persons should avoid exposure to calves and lambs and to prem-
ises where these animals are raised (BII).
(5) HIV-infected persons should not drink water directly from lakes or rivers (AIII).
(6) Waterborne infection may also result from swallowing water during recreational
activities. Patients should be aware that many lakes, rivers, and salt-water beaches
and some swimming pools and recreational water parks may be contaminated with
human or animal waste that contains Cryptosporidia. Patients should avoid swim-
ming in water that is likely to be contaminated and should avoid swallowing water
during swimming (BII).
(7) Several outbreaks of cryptosporidiosis have been linked to municipal water
supplies. During outbreaks or in other situations in which a community “boil-water”
advisory is issued, boiling water for 1 minute will eliminate the risk of crypto-
sporidiosis (AI). Use of submicron personal-use water filters* (i.e., home/office types)
and/or bottled water† may reduce the risk (CIII). The magnitude of the risk of acquiring
cryptosporidiosis from drinking water in a nonoutbreak setting is uncertain, and
current data are inadequate to recommend that all HIV-infected persons boil water or
avoid drinking tap water in nonoutbreak settings. However, HIV-infected persons who
wish to take independent action to reduce the risk of waterborne cryptosporidiosis
may choose to take precautions similar to those recommended during outbreaks.
Such decisions should be made in conjunction with health-care providers. Persons
who opt for a personal-use filter or bottled water should be aware of the complexities
involved in selecting appropriate products, the lack of enforceable standards for the
destruction or removal of oocysts, the cost of the products, and the logistic difficulty
of using these products consistently.
(8) Patients who take precautions to avoid acquiring cryptosporidiosis from drink-
ing water should be advised that ice made from contaminated tap water also can be a
source of infection (BII). Such persons also should be aware that fountain beverages
served in restaurants, bars, theaters, and other places may also pose a risk because
these beverages, as well as the ice they contain, are made from tap water. Nationally
distributed brands of bottled or canned carbonated soft drinks are safe to drink. Com-
mercially packaged noncarbonated soft drinks and fruit juices that do not require
*Only filters capable of removing particles 1 µm in diameter should be considered. Filters that
provide the greatest assurance of oocyst removal include those that operate by reverse os-
mosis, those labeled as “absolute” 1-µm filters, and those labeled as meeting NSF (National
Sanitation Foundation) standard no. 53 for “cyst removal.” The “nominal” 1-µm filter rating
is not standardized, and many filters in this category may not be capable of removing 99% of
oocysts.
†Sources of bottled water (e.g., wells, springs, municipal tap-water supplies, rivers, and lakes)
and methods for its disinfection differ; therefore, all brands should not be presumed to be
free of cryptosporidial oocysts. Water from wells and springs is much less likely to be con-
taminated by oocysts than water from rivers or lakes. Treatment of bottled water by distillation
or reverse osmosis ensures oocyst removal. Water passed through an “absolute” 1-µm filter
or a filter labeled as meeting NSF standard no. 53 for “cyst removal” before bottling will
provide nearly the same level of protection. Use of “nominal” 1-µm filters by bottlers as the
only barrier to Cryptosporidia may not result in the removal of 99% of oocysts.
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refrigeration until after they are opened (e.g., those that can be stored unrefrigerated
on grocery shelves) also are safe. Nationally distributed brands of frozen fruit juice
concentrate are safe if they are reconstituted by the user with water from a safe
source. Fruit juices that must be kept refrigerated from the time they are processed to
the time of consumption may be either fresh (unpasteurized) or heat treated (pasteur-
ized); only those juices labeled as pasteurized should be considered free of risk from
Cryptosporidium. Other pasteurized beverages and beers also are considered safe to
drink (BII). No data are available concerning survival of Cryptosporidium oocysts in
wine. 
(9) In a hospital, standard precautions (i.e., use of gloves and hand washing after
removal of gloves) should be sufficient to prevent transmission of cryptosporidiosis
from an infected patient to a susceptible HIV-infected person (BII). However, because
of the potential for fomite transmission, some experts recommend that HIV-infected
persons, especially those who are severely immunocompromised, should not share a
room with a patient with cryptosporidiosis (CIII).
Prevention of Disease
(10) No effective chemoprophylactic agents are available for cryptosporidiosis.
Prevention of Recurrence




(12) At present, no data indicate that formula-preparation practices for infants
should be altered in an effort to prevent cryptosporidiosis (CIII).
Microsporidiosis
Prevention of Exposure
(1) Other than general attention to hand washing and other personal hygiene meas-
ures, no precautions to reduce exposure can be recommended at this time.
Prevention of Disease
(2) No chemoprophylactic regimens are known to be effective in preventing
microsporidiosis.
Prevention of Recurrence
(3) No chemotherapeutic regimens are known to be effective in preventing the re-
currence of microsporidiosis.
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Tuberculosis
Prevention of Exposure
(1) HIV-infected persons should be advised that certain activities and occupations
may increase the likelihood of exposure to tuberculosis (BIII). These include volunteer
work or employment in health-care facilities, correctional institutions, and shelters for
the homeless, as well as in other settings identified as high risk by local health authori-
ties. Decisions about whether to continue with activities in these settings should be
made in conjunction with the health-care provider and should be based on factors
such as the patient’s specific duties in the workplace, the prevalence of tuberculosis in
the community, and the degree to which precautions are taken to prevent the trans-
mission of tuberculosis in the workplace (BIII). Whether the patient continues with
such activities may affect the frequency with which screening for tuberculosis needs
to be conducted.
Prevention of Disease
(2) When HIV infection is first recognized, the patient should receive a tuberculin
skin test (TST) by administration of intermediate-strength (5-TU) purified protein
derivative (PPD) by the Mantoux method (AI). Routine evaluation for anergy is not
recommended (CIII). However, there are selected situations in which anergy evalu-
ation may assist in guiding individual decisions about preventive therapy (e.g., for
TST-negative persons in populations at high risk for M. tuberculosis infection).
(3) All HIV-infected persons who have a positive result in the TST (≥5 mm of indura-
tion) should undergo chest radiography and clinical evaluation for the exclusion
of active tuberculosis. HIV-infected persons who have symptoms suggestive of
tuberculosis should undergo chest radiography and clinical evaluation regardless of
their TST status (AII).
(4) All HIV-infected persons who have a positive TST result yet have no evidence
of active tuberculosis and no history of treatment or prophylaxis for tuberculosis
should be administered 12 months of preventive chemotherapy with isoniazid (INH)
(AI). Because HIV-infected persons are at risk for peripheral neuropathy, those receiv-
ing INH should also receive pyridoxine (BIII). The decision to use alternative anti-
mycobacterial agents for chemoprophylaxis should be based on the relative risk of
exposure to resistant organisms and may require consultation with public health
authorities (AII). Rifamycin/protease inhibitor interactions need to be taken into
account when non-INH preventive therapy is considered. The need for direct observa-
tion as a means of documenting adherence to chemoprophylaxis should be
considered on an individual basis (BIII).
(5) HIV-infected persons who are close contacts of persons who have infectious
tuberculosis should be administered preventive therapy—regardless of TST results or
prior courses of chemoprophylaxis—after the diagnosis of active tuberculosis has
been excluded (AII). In addition to household contacts, such persons might also in-
clude contacts in the same drug treatment or health-care facility, coworkers, and other
contacts if transmission of TB is demonstrated. Such persons should be tested with
5-TU PPD. If the TST result is initially negative, the person should be evaluated again
3 months after the discontinuation of contact with the infectious source, and the
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information obtained should be considered in decisions about whether chemoprophy-
laxis should continue (BIII).
(6) TST-negative, HIV-infected persons from risk groups or geographic areas with a
high prevalence of M. tuberculosis infection may be at increased risk of primary or
reactivation tuberculosis. Some experts recommend preventive therapy for some per-
sons in this category (CIII). However, the efficacy of preventive therapy in this group
has not been demonstrated, and such prophylaxis cannot be routinely recommended.
Decisions concerning the use of chemoprophylaxis in these situations must be con-
sidered individually.
(7) Although the reliability of the TST may diminish as the CD4+ T-lymphocyte
count declines, annual repeat testing should be considered for HIV-infected persons
who are TST-negative on initial evaluation and who belong to populations in which
there is a substantial risk of exposure to M. tuberculosis (BIII). In addition to docu-
menting tuberculous infection, TST conversion in an HIV-infected person should alert
health-care providers to the possibility of recent M. tuberculosis transmission and
should prompt notification of public health officials for investigation to identify a pos-
sible source case.
(8) The administration of BCG vaccine to HIV-infected persons is contraindicated
because of its potential to cause disseminated disease (EII).
Prevention of Recurrence
(9) Chronic suppressive therapy for a patient who has successfully completed a
recommended regimen of treatment for tuberculosis is not necessary (DII).
Notes
Pediatric Note
(10) Infants born to HIV-infected mothers should have a TST (5-TU PPD) at or before
age 9–12 months and should be retested at least every 2–3 years (CIII). Children living
in households with M. tuberculosis-infected (TST-positive) persons should be evalu-
ated for tuberculosis (17 ) (CIII); children exposed to a person who has active
tuberculosis should be administered preventive therapy after active tuberculosis has
been excluded (AII). Decisions to discontinue prophylaxis for children who remain un-
infected after removal from exposure to a source case can be made as for adults (see
Prevention of Disease [5]).
Note Regarding Pregnancy
(11) Chemoprophylaxis for tuberculosis is recommended during pregnancy for
HIV-infected patients who have either a positive TST or a history of exposure to active
tuberculosis, after active tuberculosis has been excluded (AIII). A chest radiograph
should be obtained before treatment and appropriate abdominal/pelvic lead apron
shields should be used to minimize radiation exposure to the embryo/fetus. In the
absence of exposure to drug-resistant TB, INH is the prophylactic agent of choice.
Because of theoretical concerns regarding possible teratogenicity associated with
drug exposures during the first trimester, providers may choose to initiate prophylaxis
after the first trimester. Preventive therapy with INH should be accompanied by pyri-
doxine to reduce the risk of neurotoxicity. Experience with rifampin or rifabutin during
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pregnancy is more limited, but anecdotal experience with rifampin has not been asso-
ciated with adverse pregnancy outcomes. 
Disseminated Infection with Mycobacterium avium Complex
Prevention of Exposure
(1) Organisms of the M. avium complex (MAC) are common in environmental
sources such as food and water. Current information does not support specific recom-
mendations regarding avoidance of exposure.
Prevention of Disease
(2) Adults and adolescents who have HIV infection should receive chemoprophy-
laxis against disseminated MAC disease if they have a CD4+ T-lymphocyte count of
<50 cells/µL (AI). Clarithromycin or azithromycin are the preferred prophylactic agents
(AI). The combination of clarithromycin and rifabutin is no more effective than
clarithromycin alone for chemoprophylaxis and is associated with a higher rate of ad-
verse effects than either drug alone; this combination should not be used (EI). The
combination of azithromycin with rifabutin is more effective than azithromycin alone;
however, the additional cost, increased occurrence of adverse effects, and absence of
a difference in survival when compared with azithromycin alone do not warrant a
routine recommendation for this regimen (CI). In addition to their preventive activity
for MAC disease, clarithromycin and azithromycin confer protection against respira-
tory bacterial infections (BII). If clarithromycin or azithromycin cannot be tolerated,
rifabutin is an alternative prophylactic agent for MAC disease (BI). Before prophylaxis
is initiated, disseminated MAC disease should be ruled out by clinical assessment,
which may include obtaining a blood culture for MAC if warranted. Because treatment
with rifabutin could result in the development of resistance to rifampin in persons who
have active tuberculosis, the latter condition should also be excluded before rifabutin
is used for prophylaxis. Tolerance, cost, and drug interactions are among the issues
that should be considered in decisions regarding the choice of prophylactic agents for
MAC disease. Particular attention to interactions of antiretroviral protease inhibitors
with rifabutin and, to a lesser extent, clarithromycin, is warranted (see Drug Interac-
tion Note).
(3) Although the detection of MAC organisms in the respiratory or gastrointestinal
tract may be predictive of the development of disseminated MAC infection, no data
are available on the efficacy of prophylaxis with clarithromycin, azithromycin, rifabu-
tin, or other drugs in patients with MAC organisms at these sites and a negative blood
culture. Therefore, routine screening of respiratory or gastrointestinal specimens for
MAC cannot be recommended at this time (DIII).
Prevention of Recurrence
(4) Patients who are treated for disseminated MAC disease should continue to be
administered full therapeutic doses of antimycobacterial agents for life (AII). The
choice of the drug regimen should be made in consultation with an expert. Unless
there is good clinical or laboratory evidence of macrolide resistance, the use of a
macrolide (clarithromycin or azithromycin) is recommended in combination with at
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least one other drug (i.e., ethambutol [AII] or rifabutin [AII]). Treatment of MAC disease
with clarithromycin in a dose of 1,000 mg twice a day is associated with decreased
survival compared with clarithromycin administered 500 mg twice a day; thus, the
higher dose should not be used (EI). Clofazimine has been demonstrated not to be
effective in the treatment of MAC disease and should not be used (DII). 
Notes
Drug Interaction Note
(5) Patients concurrently being administered protease inhibitor antiretroviral ther-
apy generally should not be administered rifabutin. However, if co-administration of
rifabutin and a protease inhibitor is necessary, indinavir and nelfinavir are the pre-
ferred protease inhibitors, and the dose of rifabutin should be reduced by 50% with
either of these drugs. Although protease inhibitors may also increase clarithromycin
levels, no recommendation for dose adjustment of either clarithromycin or protease
inhibitors can be made based on existing data.
Pediatric Note
(6) HIV-infected children aged <13 years who have advanced immunosuppression
may also develop disseminated MAC infections, and prophylaxis should be offered to
high-risk children according to the following CD4+ thresholds: children aged ≥6 years,
<50 cells/µL; children aged 2–6 years, <75 cells/µL; children aged 1–2 years,
<500 cells/µL; and children aged <12 months, <750 cells/µL (AII). For the same reasons
that clarithromycin and azithromycin are the preferred prophylactic agents for adults,
they should also be considered for children (AII); oral suspensions of both are com-
mercially available in the United States. A liquid formulation of rifabutin suitable for
pediatric use is under development but currently is not commercially available in the
United States.
Note Regarding Pregnancy
(7) Chemoprophylaxis for MAC disease should be administered to pregnant
women as well as to other adults and adolescents (AIII). However, because of general
concern about administering drugs during the first trimester of pregnancy, some
providers may choose to withhold prophylaxis during the first trimester. Of the avail-
able agents, the safety profile in animal studies and anecdotal safety in humans
suggest that azithromycin is the drug of choice (BIII). Experience with rifabutin is lim-
ited. Clarithromycin has been demonstrated to be a teratogen in animals and should
be used with caution during pregnancy.
Bacterial Respiratory Infections
Prevention of Exposure
(1) Because Streptococcus pneumoniae and Haemophilus influenzae are common
in the community, there is no effective way to reduce exposure to these bacteria.
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Prevention of Disease
(2) As soon as feasible after HIV infection is diagnosed, adults and adolescents who
have a CD4+ T-lymphocyte count of ≥200 cells/µL should be administered a single
dose of 23-valent polysaccharide pneumococcal vaccine if they have not had this vac-
cine during the previous 5 years (AII). For persons who have a CD4+ T-lymphocyte
count of <200 cells/µL, vaccination should be offered, although the humoral response
and, therefore, clinical efficacy are likely to be diminished (CIII). The recommendation
to vaccinate is increasingly pertinent because of the increasing incidence of invasive
infections with drug-resistant (including TMP-SMZ–resistant and macrolide-resistant)
strains of S. pneumoniae. Limited data suggest that administration of certain bacterial
vaccines may transiently increase HIV replication and plasma HIV-1 RNA levels in HIV-
infected persons who are not being administered potent antiretroviral regimens.
However, evidence that adverse clinical outcomes are associated with this transient
increase is lacking. Most experts believe that the benefit of pneumococcal vaccination
outweighs the potential risk. 
(3) The duration of the protective effect afforded by primary pneumococcal vacci-
nation is unknown. Revaccination once should be considered for HIV-infected
persons, provided that at least 5 years have elapsed since administration of the first
dose of pneumococcal vaccine (CIII).
(4) The incidence of H. influenzae type B infection in adults is low. Therefore, H. in-
fluenzae type B vaccine is not generally recommended for adult use (DIII).
(5) TMP-SMZ, administered daily, reduces the frequency of bacterial respiratory
infections; this should be considered in the selection of an agent for PCP prophylaxis
(AII). However, indiscriminate use of this drug (when not indicated for PCP prophylaxis
or other specific reasons) may promote the development of TMP-SMZ–resistant
organisms. Thus, TMP-SMZ should not be prescribed solely to prevent bacterial respi-
ratory infection (DIII). Similarly, clarithromycin administered daily and azithromycin
administered weekly are effective in preventing bacterial respiratory infections. This
should be considered in the selection of an agent for prophylaxis of MAC disease (BII),
although again, these drugs should not be prescribed solely for preventing bacterial
respiratory infection (DIII).
(6) An absolute neutrophil count that is depressed because of HIV disease or
drug therapy may be increased by granulocyte colony-stimulating factor (G-CSF) or
granulocyte-macrophage colony-stimulating factor (GM-CSF). The use of G-CSF or
GM-CSF to prevent bacterial infections in HIV-infected patients with neutropenia can-
not be recommended (CIII). However, preliminary data suggest that G-CSF can
provide benefit for selected patients.
Prevention of Recurrence
(7) Some clinicians may administer antibiotic chemoprophylaxis to HIV-infected pa-
tients who have very frequent recurrences of serious bacterial respiratory infections
(CIII). TMP-SMZ, administered for PCP prophylaxis, and clarithromycin or azithromy-
cin, administered for MAC prophylaxis, are appropriate for drug-sensitive organisms.
However, providers should be cautious about use of antibiotics for this purpose be-
cause of the potential for development of drug-resistant microorganisms.
(8) All invasive pneumococcal isolates from HIV-infected patients should be tested
for susceptibility to β-lactam antibiotics, and local patterns of resistance should
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be considered in the choice of regimens for empirical treatment (AII). Invasive infec-
tions caused by H. influenzae should be treated with regimens effective against
β-lactamase–producing strains until drug susceptibilities are known (AII).
Notes
Pediatric Notes
(9) Children who have HIV infection should be administered H. influenzae type b
vaccine in accordance with the guidelines of the Advisory Committee on Immuniza-
tion Practices (18 ) and the American Academy of Pediatrics (17 ) (AII). Children aged
>2 years also should be administered 23-valent polysaccharide pneumococcal vaccine
(AII). Revaccination with pneumococcal vaccine generally should be offered after
3–5 years to children aged ≤10 years and after 5 years to children aged >10 years (BIII).
(10) To prevent serious bacterial infections in HIV-infected children who have
hypogammaglobulinemia, clinicians should use intravenous immunoglobulin (IVIG)
(AI). Respiratory syncytial virus (RSV) IVIG may be substituted for IVIG during the RSV
season.
(11) To prevent recurrence of serious bacterial respiratory infections, antibiotic
chemoprophylaxis should be considered (BI). However, providers should be cautious
about use of antibiotics for this purpose because of the potential for development of
drug-resistant microorganisms. The administration of IVIG should also be considered
for HIV-infected children who have recurrent serious bacterial infections (BI), but such
treatment may not provide additional benefit to children who are being administered
daily TMP-SMZ.
Note Regarding Pregnancy
(12) Pneumococcal vaccination is recommended during pregnancy for patients
who have not been vaccinated during the previous 5 years (AIII). In nonpregnant
adults, vaccination has been associated with a transient burst of HIV replication. It is
unknown whether the transient viremia can increase the risk of perinatal HIV transmis-
sion. Because of this concern, when feasible, vaccination may be deferred until after





(1) Health-care providers should advise HIV-infected persons not to eat raw or un-
dercooked eggs (including foods that may contain raw eggs [e.g., some preparations
of hollandaise sauce, Caesar and other salad dressings, and mayonnaise]); raw or un-
dercooked poultry, meat, or seafood; or unpasteurized dairy products. Poultry and
meat should be well cooked and should not be pink in the middle (internal tempera-
ture >165 F [73.8 C]). Produce should be washed thoroughly before being eaten (BIII).
(2) Health-care providers should advise HIV-infected persons to avoid cross-
contamination of foods. For example, uncooked meats should not come into contact
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with other foods, and hands, cutting boards, counters, and knives and other utensils
should be washed thoroughly after contact with uncooked foods (BIII).
(3) Health-care providers should advise HIV-infected persons that, although the in-
cidence of listeriosis is low, it is a serious disease that occurs with unusually high
frequency among HIV-infected persons who are severely immunosuppressed. Such
persons may choose to avoid soft cheeses because some studies have shown an as-
sociation between these foods and listeriosis. These studies also have documented an
association between ready-to-eat foods (e.g., hot dogs and cold cuts from delicates-
sen counters) and listeriosis. An immunosuppressed, HIV-infected person who wishes
to reduce the risk of foodborne disease as much as possible may choose to reheat
such foods until they are steaming hot before eating them (CIII).
Pets
(4) When obtaining a new pet, HIV-infected persons should avoid young animals
(aged <6 months), especially those that have diarrhea (BIII).
(5) HIV-infected persons should avoid contact with animals that have diarrhea (BIII).
HIV-infected pet owners should seek veterinary care for animals with diarrheal illness,
and a fecal sample from such animals should be examined for Cryptosporidium, Sal-
monella, and Campylobacter.
(6) HIV-infected persons should wash their hands after handling pets (especially
before eating) and should avoid contact with pets’ feces (BIII).
(7) HIV-infected persons should avoid contact with reptiles (e.g., snakes, lizards,
iguanas, and turtles) because of the risk of salmonellosis (BIII).
Travel
(8) The risk of food- and waterborne infections among immunosuppressed, HIV-
infected persons is magnified during travel to developing countries. Those who elect
to travel to such countries should avoid foods and beverages that may be contami-
nated, particularly raw fruits and vegetables, raw or undercooked seafood or meat,
tap water, ice made with tap water, unpasteurized milk and dairy products, and items
sold by street vendors (AII). Foods and beverages that are generally safe include
steaming-hot foods, fruits that are peeled by the traveler, bottled (especially carbon-
ated) beverages, hot coffee and tea, beer, wine, and water brought to a rolling boil for
1 minute (AII). Treatment of water with iodine or chlorine may not be as effective as
boiling but can be used when boiling is not practical (BIII).
Prevention of Disease
(9) Prophylactic antimicrobial agents are not generally recommended for travelers
(DIII). The effectiveness of these agents depends on local antimicrobial-resistance pat-
terns of gastrointestinal pathogens, which are seldom known. Moreover, these agents
can elicit adverse reactions and can promote the emergence of resistant organisms.
However, for HIV-infected travelers, antimicrobial prophylaxis may be considered, de-
pending on the level of immunosuppression and the region and duration of travel
(CIII).
The use of fluoroquinolones such as ciprofloxacin (500 mg/d) can be considered
when prophylaxis is deemed necessary (BIII). As an alternative (e.g., for children,
pregnant women, and persons already taking TMP-SMZ for PCP prophylaxis),
16 MMWR June 27, 1997
TMP-SMZ may offer some protection against traveler’s diarrhea (BIII). The risk of tox-
icity should be considered before treatment with TMP-SMZ is initiated solely because
of travel.
(10) Antimicrobial agents such as fluoroquinolones (e.g., 500 mg of ciprofloxacin
twice a day for 3–7 days) should be given to patients before their departure, to be
taken empirically should traveler’s diarrhea develop (BIII). Alternative antibiotics for
children and pregnant women should be discussed (CIII). Travelers should consult a
physician if their diarrhea is severe and does not respond to empirical therapy, if their
stools contain blood, if fever is accompanied by shaking chills, or if dehydration devel-
ops. Antiperistaltic agents (e.g., diphenoxylate and loperamide) can be used for the
treatment of mild diarrhea. However, the use of these drugs should be discontinued if
symptoms persist beyond 48 hours. Moreover, these agents should not be adminis-
tered to patients who have a high fever or who have blood in the stool (AII).
(11) Some experts recommend that HIV-infected persons who have Salmonella
gastroenteritis be administered antimicrobial therapy to prevent extraintestinal
spread. However, no controlled study has demonstrated a beneficial effect of such
treatment, and some studies of immunocompetent persons have suggested that an-
timicrobial therapy can lengthen the shedding period. The fluoroquinolones—
primarily ciprofloxacin (750 mg twice a day for 14 days)—can be used when antimicro-
bial therapy is chosen (CIII).
Prevention of Recurrence
(12) HIV-infected persons who have Salmonella septicemia require long-term ther-
apy for the prevention of recurrence. The fluoroquinolones, primarily ciprofloxacin,
are usually the drugs of choice for susceptible organisms (BII).
(13) Household contacts of HIV-infected persons who have salmonellosis or shigel-
losis should be evaluated for asymptomatic carriage of Salmonella or Shigella so that
strict hygienic measures and/or antimicrobial therapy can be instituted and recurrent
transmission to the HIV-infected person can be prevented (CIII).
Notes
Pediatric Notes
(14) Like HIV-infected adults, HIV-infected children should wash their hands after
handling pets (especially before eating) and should avoid contact with pets’ feces.
Hand washing should be supervised (BIII).
(15) HIV-exposed infants aged <3 months and all HIV-infected children who have
severe immunosuppression should be administered treatment for Salmonella gastro-
enteritis to prevent extraintestinal spread (CIII). Possible choices of antibiotics include
TMP-SMZ, ampicillin, cefotaxime, ceftriaxone, or chloramphenicol; ciprofloxacin
should be used with caution and only if no alternatives exist.
(16) HIV-infected children who have Salmonella septicemia should be offered long-
term therapy for the prevention of recurrence (CIII). TMP-SMZ is the drug of choice;
ampicillin or chloramphenicol can be used if the organism is susceptible. Ciproflox-
acin should be used with caution and only if no alternatives exist.
(17) Antiperistaltic drugs are not recommended for children (DIII).
Vol. 46 / No. RR-12 MMWR 17
Notes Regarding Pregnancy
(18) Because both pregnancy and HIV infection confer a risk for listeriosis, pregnant
HIV-infected women should heed recommendations concerned with this disease (BII).
(19) Fluoroquinolones should not be used during pregnancy. TMP-SMZ may offer
some protection against traveler’s diarrhea.
Infection with Bartonella (Formerly Rochalimaea )
Prevention of Exposure
(1) HIV-infected persons, particularly those who are severely immunosuppressed,
are at unusually high risk of developing relatively severe disease due to Bartonella
species. These persons should consider the potential risks of cat ownership (CIII).
Those who elect to acquire a cat should adopt or purchase an older animal (aged
>1 year) that is in good health (BII).
(2) Although declawing is not generally advised, HIV-infected persons should avoid
rough play with cats and situations in which scratches are likely (BII). Any cat-
associated wound should be washed promptly (CIII). HIV-infected persons should not
allow cats to lick open cuts or wounds (BIII).
(3) Care of cats should include flea control (CIII).
(4) There is no evidence of benefit to cat or owner from routine culture or serologic
testing of the pet for Bartonella infection (DII).
Prevention of Disease
(5) No data currently support chemoprophylaxis for Bartonella-associated disease
(CIII).
Prevention of Recurrence
(6) Relapse or reinfection with Bartonella has sometimes followed a course
of primary treatment. Although no firm recommendation can be made regarding
prophylaxis in this situation, long-term suppression of infection with erythromycin or
doxycycline should be considered (CIII).
Note
Pediatric Note
(7) The risks of cat ownership for HIV-infected children who are severely immuno-
compromised should be discussed with parents/caretakers (CIII).
Candidiasis
Prevention of Exposure
(1) Candida organisms are common on mucosal surfaces and skin. No measures
are available to reduce exposure to these fungi.
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Prevention of Disease
(2) Data from a prospective controlled trial indicate that fluconazole can reduce
the risk of mucosal (oropharyngeal, esophageal, and vaginal) candidiasis (and crypto-
coccosis as well) in patients with advanced HIV disease. However, routine primary
prophylaxis is not recommended because of the effectiveness of therapy for acute
disease, the low mortality associated with mucosal candidiasis, the potential for resis-
tant Candida organisms to develop, the possibility of drug interactions, and the cost of
prophylaxis (CI).
Prevention of Recurrence
(3) Many experts do not recommend chronic prophylaxis of recurrent oro-
pharyngeal or vulvovaginal candidiasis for the same reasons that they do not rec-
ommend primary prophylaxis. However, if recurrences are frequent or severe, inter-
mittent or chronic administration of an oral azole (fluconazole [AI], ketoconazole [CIII],
or itraconazole [CIII]) may be considered. Other factors that influence choices about
such therapy include the impact of the recurrences on the patient’s well-being and
quality of life, the need for prophylaxis for other fungal infections, cost, toxicities, and
drug interactions.
(4) Adults or adolescents who have a history of documented esophageal candidi-
asis, particularly multiple episodes, should be considered candidates for chronic
suppressive therapy with fluconazole (BI).
Notes
Pediatric Notes
(5) Primary prophylaxis of candidiasis in HIV-infected infants is not indicated (DIII).
(6) Suppressive therapy with systemic azoles should be considered for infants who
have severe recurrent mucocutaneous candidiasis (BIII) and particularly for those who
have esophageal candidiasis (BI).
Note Regarding Pregnancy
(7) There is limited experience with the chronic use of antimycotic drugs during
human pregnancy; three cases of infants born with craniofacial and skeletal abnor-
malities following prolonged in-utero exosure to fluconazole have been reported.
Therefore, chemoprophylaxis against oropharyngeal, esophageal, or vaginal candidi-
asis should not be initiated during pregnancy (DIII). The drug should be discontinued
for patients who conceive while being administered the drug.
Cryptococcosis
Prevention of Exposure
(1) Although HIV-infected persons cannot completely avoid exposure to Cryptococ-
cus neoformans, avoiding sites that are likely to be heavily contaminated with
C. neoformans (e.g., areas heavily contaminated with pigeon droppings) may reduce
the risk of infection.
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Prevention of Disease
(2) Routine testing of asymptomatic persons for serum cryptococcal antigen is not
recommended because of the low probability that the results will affect clinical deci-
sions (DIII).
(3) Data from prospective controlled trials indicate that fluconazole and itracona-
zole can reduce the frequency of cryptococcal disease among patients who have
advanced HIV disease. Therefore, providers may wish to consider prophylaxis for per-
sons who have a CD4+ T-lymphocyte count of <50 cells/µL (CI). However, most experts
recommend that antifungal prophylaxis not be used routinely to prevent cryptococ-
cosis because of the relative infrequency of cryptococcal disease, the lack of survival
benefit associated with prophylaxis, the possibility of drug interactions, the potential
for development of both Candida and Cryptococcus drug resistance, and cost. The
need for prophylaxis or suppressive therapy for other fungal infections (e.g., candidi-
asis or histoplasmosis) should be considered in making decisions about prophylaxis
for cryptococcosis. Doses of fluconazole ranging from 400 mg once a week to 200 mg
daily are effective as prophylaxis against cryptococcosis; however, doses of <200 mg
daily may be less effective in suppressing Candida infections, and fluconazole may not
prevent Histoplasma infection. 
Prevention of Recurrence
(4) Patients who complete initial therapy for cryptococcosis should be administered
lifelong suppressive treatment with fluconazole (AI).
Notes
Pediatric Note
(5) There are no data on which to base specific recommendations for children, but
lifelong suppressive therapy with fluconazole after an episode of cryptococcosis is
appropriate (AII).
Note Regarding Pregnancy
(6) Prophylaxis with fluconazole or itraconazole should not be initiated during preg-
nancy because of the low incidence of cryptococcal disease, the lack of a
recommendation for primary prophylaxis against cryptococcosis in nonpregnant
adults, and the potential for adverse effects of these drugs during pregnancy (DIII). For
patients who conceive while being administered primary prophylaxis, prophylaxis
should be discontinued. However, because of the risk of the disease to maternal
health, prophylaxis against recurrent cryptococcal disease with fluconazole during
pregnancy is indicated (AIII).
Histoplasmosis
Prevention of Exposure
(1) Although HIV-infected persons living in or visiting histoplasmosis-endemic
areas cannot completely avoid exposure to Histoplasma capsulatum, they should
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avoid activities known to be associated with increased risk (e.g., cleaning chicken
coops, disturbing soil beneath bird-roosting sites, and exploring caves) (CIII).
Prevention of Disease
(2) Routine skin testing with histoplasmin in histoplasmosis-endemic areas is not
predictive of disease and should not be performed (EII).
(3) Data from a prospective controlled trial indicate that itraconazole can reduce the
frequency of histoplasmosis among patients who have advanced HIV infection and
who live in areas in which H. capsulatum is endemic; thus, physicians may wish to
consider chemoprophylaxis for adult and adolescent patients who live in an area en-
demic for H. capsulatum and who have a CD4+ T-lymphocyte count of <100 cells/µL
(CI). However, when deciding on such prophylaxis, physicians should consider the
possibility of drug interactions, toxicity, development of resistance, and the cost of
prophylaxis. The need for prophylaxis or suppressive therapy for other fungal infec-
tions (e.g., cryptococcosis and candidiasis) should be considered when making
decisions about prophylaxis for histoplasmosis. Itraconazole has not been demon-
strated conclusively to prevent candidiasis, although it has activity for chronic
suppression of cryptococcosis. 
Prevention of Recurrence
(4) Patients who complete initial therapy should be administered lifelong suppres-
sive treatment with itraconazole (AII).
Notes
Pediatric Note
(5) Because primary histoplasmosis can lead to disseminated infection in children,
it is reasonable to administer lifelong suppressive therapy after an acute episode of
the disease (AIII).
Note Regarding Pregnancy
(6) Itraconazole is embryotoxic and teratogenic in animal systems. Therefore,
primary prophylaxis against histoplasmosis is not indicated during pregnancy (DIII).
However, because of the risk of the disease to maternal health, prophylaxis against
recurrent histoplasmosis is indicated (AIII).
Coccidioidomycosis
Prevention of Exposure
(1) Although HIV-infected persons living in or visiting areas in which coccidioi-
domycosis is endemic cannot completely avoid exposure to Coccidioides immitis,
they should, when possible, avoid activities associated with increased risk (e.g., those
involving extensive exposure to disturbed native soil, for example, at building excava-
tion sites or during dust storms) (CIII).
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Prevention of Disease
(2) Routine skin testing with coccidioidin (spherulin) in coccidioidomycosis-
endemic areas is not predictive of disease and should not be performed (EII).
(3) No recommendation can be made regarding routine chemoprophylaxis for HIV-
infected persons who live in coccidioidomycosis-endemic areas or for skin test-
positive persons who live in areas where coccidioidomycosis is not endemic.
Prevention of Recurrence
(4) Patients who complete initial therapy for coccidioidomycosis should be admin-
istered lifelong systemic suppressive treatment (AII). Fluconazole is the preferred
agent; alternative drugs include itraconazole and amphotericin B.
Notes
Pediatric Note
(5) Although no specific data are available regarding coccidioidomycosis in HIV-
infected children, it is reasonable to administer lifelong suppressive therapy after an
acute episode of the disease (AIII).
Note Regarding Pregnancy
(6) Because of the risk to maternal health posed by coccidioidomycosis, prophy-
laxis against recurrent coccidioidomycosis is indicated during pregnancy (AIII).
Cytomegalovirus Disease
Prevention of Exposure
(1) HIV-infected persons who belong to risk groups with relatively low rates of sero-
positivity for cytomegalovirus (CMV) and who anticipate possible exposure to CMV
(e.g., through blood transfusion or employment in a child-care facility) should be
tested for antibody to CMV (BIII). These groups include patients who have not had
male homosexual contact and those who are not injecting-drug users.
(2) HIV-infected adolescents and adults should be advised that CMV is shed in se-
men, cervical secretions, and saliva and that latex condoms must always be used
during sexual contact to reduce the risk of exposure to CMV and to other sexually
transmitted pathogens (AII).
(3) HIV-infected adults and adolescents who are child-care providers or parents of
children in child-care facilities should be informed that they—like all children at these
facilities—are at increased risk of acquiring CMV infection (BI). Parents and other care-
takers of HIV-infected children should be advised of the increased risk to children at
these centers (BIII). The risk of acquiring CMV infection can be diminished by good
hygienic practices such as hand washing (AII).
(4) HIV-exposed infants and HIV-infected children, adolescents, and adults who
are seronegative for CMV and require blood transfusion should be administered only
CMV antibody-negative or leukocyte-reduced cellular blood products in nonemer-
gency situations (BIII).
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Prevention of Disease
(5) Prophylaxis with oral ganciclovir may be considered for HIV-infected adults and
adolescents who are CMV seropositive and who have a CD4+ T-lymphocyte count of
<50 cells/µL (CI). Neutropenia, anemia, limited efficacy, lack of improvement in sur-
vival, and cost are among the issues that should be considered in decisions about
whether to institute prophylaxis in individual patients. Acyclovir is not effective in
preventing CMV disease, and valaciclovir is not recommended because of an unex-
plained trend toward increased mortality observed in persons who have AIDS and
who were administered this drug for CMV prophylaxis. Therefore, neither acyclovir
nor valaciclovir should be used for this purpose (EI). The most important method for
preventing severe CMV disease is recognition of the early manifestations of the dis-
ease. Early recognition of CMV retinitis is most likely when the patient has been
educated on this topic. Patients should be made aware of the significance of increased
“floaters” in the eye and should be advised to assess their visual acuity regularly by
simple techniques such as reading newsprint (BIII). Regular funduscopic examinations
performed by a health-care provider or specifically by an ophthalmologist are recom-
mended by some experts for patients with low (e.g., <100 cells/µL) CD4+ T-lymphocyte
counts (CIII). 
Prevention of Recurrence
(6) CMV disease is not cured with courses of the currently available antiviral agents
(i.e., ganciclovir, foscarnet, or cidofovir). Chronic suppressive or maintenance therapy
is indicated. Effective regimens include parenteral or oral ganciclovir, parenteral
foscarnet, combined parenteral ganciclovir and foscarnet, parenteral cidofovir, and
(for retinitis only) ganciclovir administration via intraocular implant (AI). The intraocu-
lar implant does not provide protection to the contralateral eye or to other organ
systems. In spite of maintenance therapy, recurrences develop routinely and require
reinstitution of high-dose induction therapy or replacement of the implant.
Notes
Pediatric Note
(7) Some experts recommend obtaining a CMV urine culture on all HIV-infected (or
exposed) infants at birth or at an early postnatal visit to identify those infants with
congenital CMV infection (CIII). In addition, beginning at 1 year of age, CMV antibody
testing on an annual basis may be considered for CMV-seronegative (and culture-
negative) HIV-infected infants and children who are severely immunosuppressed
(Table 1) (CIII). Annual testing will allow identification of children who have acquired
CMV infection and might benefit from screening for retinitis.
(8) HIV-infected children who are CMV-infected and severely immunosuppressed
may benefit from a dilated retinal examination performed by an ophthalmologist
every 4–6 months (CIII). In addition, older children should be counseled to be aware of
“floaters” in the eye, similar to the recommendation for adults (BIII).
(9) Oral ganciclovir is currently under investigation in CMV-infected children, and
no recommendation about its use can be made at this time.
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Note Regarding Pregnancy
(10) Because of the lack of recommendation for its routine use in nonpregnant
adults and the lack of experience with this drug during pregnancy, ganciclovir is not
recommended for primary prophylaxis against CMV disease during pregnancy (DIII).
Ganciclovir should be discontinued for patients who conceive while being adminis-
tered primary prophylaxis. Because of the risks to maternal health, prophylaxis
against recurrent CMV disease is indicated during pregnancy (AIII). The choice of
agents to be used in pregnancy should be individualized after consultation with
experts.
Herpes Simplex Virus Disease
Prevention of Exposure
(1) HIV-infected persons should use latex condoms during every act of sexual inter-
course to reduce the risk of exposure to herpes simplex virus (HSV) and to other
sexually transmitted pathogens (AII). They should specifically avoid sexual contact
when herpetic lesions (genital or orolabial) are evident (AII).
Prevention of Disease
(2) Prophylaxis of initial episodes of HSV disease is not recommended (DIII).
Prevention of Recurrence
(3) Because acute episodes of HSV infection can be treated successfully, chronic
therapy with acyclovir is not required after lesions resolve. However, persons who
have frequent or severe recurrences can be administered daily suppressive therapy
with oral acyclovir (AI). Intravenous foscarnet or cidofovir can be used to treat infec-
tion due to acyclovir-resistant isolates of HSV, which are routinely resistant to gan-
ciclovir as well (AII). Topical preparations of foscarnet and cidofovir also are available.
Notes
Pediatric Note
(4) The recommendations for the prevention of initial disease and recurrence apply
to children as well as to adolescents and adults.
Note Regarding Pregnancy
(5) Oral acyclovir prophylaxis in late pregnancy is a controversial strategy recom-
mended by some experts to prevent neonatal herpes transmission. However, such
prophylaxis is not routinely recommended. For patients who have frequent, severe
recurrences of genital HSV disease, acyclovir prophylaxis may be indicated (BIII). No
pattern of adverse pregnancy outcomes has been reported after acyclovir exposures.
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Varicella-Zoster Virus Infection
Prevention of Exposure
(1) HIV-infected children and adults who are susceptible to varicella-zoster virus
(VZV) (i.e., those who have no history of chickenpox or shingles or are seronegative
for VZV) should avoid exposure to persons with chickenpox or shingles (AII). Although
vaccination against varicella is currently under investigation in HIV-infected children,
based on current information, vaccine against varicella should not be administered to
adults or children who are infected with HIV because of the potential for disseminated
viral infection (EIII). Household contacts (especially children) of susceptible HIV-
infected persons should be vaccinated against VZV if they have no history of chicken-
pox and are seronegative for HIV, so that they will not transmit VZV to their
susceptible HIV-infected contact (BIII).
Prevention of Disease
(2) For the prophylaxis of chickenpox, HIV-infected children and adults who are sus-
ceptible to VZV (i.e., those who have no history of chickenpox or shingles or who have
no detectable antibody against VZV) should be administered varicella zoster immune
globulin (VZIG) as soon as possible but within 96 hours after close contact with a pa-
tient who has chickenpox or shingles (AIII). Data are lacking on the effectiveness of
acyclovir for preventing chickenpox in susceptible HIV-infected children or adults, al-
though such an approach would be logical (CIII). 
(3) No preventive measures are currently available for shingles.
Prevention of Recurrence




(5) VZIG is recommended for VZV-susceptible pregnant women within 96 hours
after exposure to VZV (AIII). If oral acyclovir is used, VZV serology should be per-
formed so that the drug can be discontinued if the patient is seropositive for VZV (BIII).
Human Papillomavirus Infection
Prevention of Exposure
(1) HIV-infected persons should use latex condoms during every act of sexual inter-
course to reduce the risk of exposure to human papillomavirus (HPV) as well as to
other sexually transmitted pathogens (AIII).
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Prevention of Disease
HPV-associated genital epithelial cancers in HIV-infected women
(2) After a complete history of previous cervical disease has been obtained, HIV-
infected women should have a pelvic examination and a Pap smear. In accordance
with the recommendation of the Agency for Health Care Policy and Research (13), the
Pap smear should be obtained twice in the first year after diagnosis of HIV infection
and, if the results are normal, annually thereafter (AII).
(3) If the results of the Pap smear are abnormal, care should be provided according
to the Interim Guidelines for Management of Abnormal Cervical Cytology published
by a National Cancer Institute Consensus Panel (19 ) and briefly summarized below.
(4) For patients whose Pap smears are interpreted as atypical squamous cells of
undetermined significance (ASCUS), several management options are available; the
choice depends in part on whether the interpretation of ASCUS is qualified by a state-
ment indicating that a neoplastic process is favored. Follow-up by Pap tests without
colposcopy is acceptable, particularly when the diagnosis of ASCUS is not qualified
further or the cytopathologist favors a reactive process. In such situations, Pap tests
should be repeated every 4–6 months for 2 years until three consecutive smears have
been negative. If a second report of ASCUS occurs in the 2-year follow-up period, the
patient should be considered for colposcopic evaluation (BIII). 
Women who have a diagnosis of unqualified ASCUS associated with severe inflam-
mation should be evaluated for an infectious process. If specific infections are
identified, reevaluation should be performed after appropriate treatment, preferably
after 2–3 months (BIII).
If the diagnosis of ASCUS is qualified by a statement indicating that a neoplastic
process is favored, the patient should be managed as if a low-grade squamous in-
traepithelial lesion (LSIL) were present (see note [5]) (BIII).
If a patient who has a diagnosis of ASCUS is at high risk (i.e., previous positive Pap
tests or poor compliance with follow-up), the option of colposcopy should be consid-
ered (BIII).
(5) Several management options are available for patients who have LSIL. Follow-
up with Pap tests every 4–6 months is used by many clinicians and is currently used in
countries outside the United States as an established method of management.
Patients managed in this fashion must be carefully selected and considered reliable
for follow-up. If repeat smears show persistent abnormalities, colposcopy and di-
rected biopsy are indicated (BIII). Colposcopy and directed biopsy of any abnormal
area on the ectocervix constitute another appropriate option (BIII).
(6) Women who have cytologic diagnosis of high-grade squamous intraepithelial
lesions (HSIL) or squamous cell carcinoma should undergo colposcopy and directed
biopsy (AII).
HPV-associated anal intraepithelial neoplasia and anal cancer in HIV-infected men
who have sex with men
(7) Although the risks for anal intraepithelial neoplasia (AIN) and anal cancer are
increased among HIV-infected men who have sex with men, the role of anal cytologic
screening and treatment of AIN in preventing anal cancer in these men is not well
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defined. Therefore, no recommendations can be made for periodic anal cytologic
screening for the detection and treatment of AIN.
Prevention of Recurrence
(8) The risks for recurrence of squamous intraepithelial lesions and cervical cancer
after conventional therapy are increased among HIV-infected women. The prevention
of illness associated with recurrence depends on careful follow-up of patients after
treatment. Patients should be monitored with frequent cytologic screening and, when
indicated, with colposcopic examination for recurrent lesions (AI).
IMMUNOLOGIC CATEGORIES FOR HIV-INFECTED CHILDREN
TABLE 1. Immunologic categories for HIV-infected children based on age-specific CD4+
T-lymphocyte counts and percentage of total lymphocytes*
Immunologic category
Age
<12 months 1–5 years 6–12 years
cells/µL (%)† cells/µL (%) cells/µL (%)
No evidence of
suppression ≥1,500 (≥25) ≥1,000 (≥25) ≥500 (≥25)
Evidence of moderate
suppression 750–1,499 (15–24) 500–999 (15–24) 200–499 (15–24)
Severe suppression <750 (<15) <500 (<15) <200 (<15)
*Adapted from 1994 revised classification system for human immunodeficiency virus infection
in children aged <13 years (16 ).
†Percentage of total lymphocytes.
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DRUG REGIMENS FOR ADULTS AND ADOLESCENTS
TABLE 2A. Prophylaxis for first episode of opportunistic disease in HIV-infected adults




I. Strongly recommended as standard of care
Pneumocystis
carinii*






(TMP-SMZ), 1 DS po q.d.
(AI);
TMP-SMZ, 1 SS po q.d. (AI)
TMP-SMZ, 1 DS po t.i.w.
(BIII); dapsone, 50 mg po
b.i.d. or 100 mg po q.d. (BI);
dapsone, 50 mg po q.d.
plus pyrimethamine, 50 mg
po q.w. plus leucovorin,
25 mg po q.w. (BI);
dapsone, 200 mg po plus
pyrimethamine, 75 mg po
plus leucovorin, 25 mg po
q.w. (BI); aerosolized











with case of active
tuberculosis
Isoniazid, 300 mg po plus
pyridoxine, 50 mg po q.d. x
12 mo (AI) or isoniazid,
900 mg po plus pyridoxine,
50 mg po b.i.w. x 12 mo (BIII)








Rifampin, 600 mg po q.d. x
12 mo (BII)
















Toxoplasma  and CD4+
count <100/µL
TMP-SMZ, 1 DS po q.d. (AII) TMP-SMZ, 1 SS po q.d. (BIII):
dapsone, 50 mg po q.d.
plus pyrimethamine, 50 mg
po q.w. plus leucovorin,
25 mg po q.w. (BI)
Mycobacterium
avium complex¶
CD4+ count <50µL Clarithromycin, 500 mg po
b.i.d. (AI) or azithromycin,
1,200 mg po q.w. (AI)
Rifabutin, 300 mg po q.d. (BI);
azithromycin, 1,200 mg po




All patients Pneumococcal vaccine, 0.5 mL







for patients who have





globulin (VZIG), 5 vials
(1.25 mL each) im,
administered ≤96 h after
exposure, ideally within 48 h
(AIII)
Acyclovir, 800 mg po
5 times/d for 3 weeks (CIII)
II. Generally recommended
Hepatitis B virus†† All susceptible
(anti-HBc-negative)
patients
Engerix B®, 20 µg im x 3 (BII);
or Recombivax HB®, 10 µg
im x 3 (BII)
None
Influenza virus†† All patients (annually,
before influenza
season)
Whole or split virus, 0.5 mL
im/yr (BIII)
Rimantadine, 100 mg po
b.i.d. (CIII) or amantadine,
100 mg po b.i.d. (CIII)
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III. Not recommended for most patients; indicated for use only in unusual circumstances
Candida species CD4+ count <50/µL Fluconazole, 100–200 mg po
q.d. (CI)
Bacteria Neutropenia Granulocyte-colony–stimulating
factor (G-CSF), 5–10 µg/kg sc
q.d. x 2–4w or
granulocyte-macrophage
colony-stimulating factor
(GM-CSF), 250 µg/m2 iv over
2 h q.d. x 2–4w (CIII)
Cryptococcus
neoformans§§
CD4+ count <50/µL Fluconazole, 100–200 mg po
q.d. (CI)











CD4+ count <50/µL and
CMV antibody positivity
Oral ganciclovir, 1 g po t.i.d.
(CI)
None
     NOTE: Information included in these guidelines may not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms “safe”
and “effective” may not be synonymous with the FDA-defined legal standards for product approval. Anti-HBc =
antibody to hepatitis B core antigen; b.i.w. = twice a week; CMV = cytomegalovirus; DS = double-strength tablet;
q.m. = monthly; q.w. = weekly; SS = single-strength tablet; t.i.w. = three times a week; TMP-SMZ = trimethoprim-
sulfamethoxazole; and TST = tuberculin skin test. The Respirgard IITM nebulizer is manufactured by Marquest,
Englewood, CO; Engerix-B® by SmithKline Beecham, Rixensart, Belgium; and Recombivax HB® by Merck & Co.,
West Point, PA. Letters and Roman numerals in parentheses after regimens indicate the strength of the
recommendation and the quality of evidence supporting it (see text).
 * Patients receiving dapsone should be tested for glucose-6 phosphate dehydrogenase deficiency. A dosage of 50
mg q.d. is probably less effective than that of 100 mg q.d. The efficacy of parenteral pentamidine (e.g., 4
mg/kg/month) is uncertain. Inadequate data are available regarding efficacy or safety of atovaquone or
clindamycin-primaquine. Fansidar (sulfadoxine-pyrimethamine) is rarely used because of severe hypersensitivity
reactions. TMP-SMZ reduces the frequency of some bacterial infections. Patients who are being administered
therapy for toxoplasmosis with sulfadiazine-pyrimethamine are protected against Pneumocystis carinii
pneumonia and do not need TMP-SMZ.
 
†
Directly observed therapy required for isoniazid (INH), 900 mg b.i.w.; INH regimens should include pyridoxine
to prevent peripheral neuropathy. Rifampin should not be administered concurrently with protease inhibitors
(20). Rifabutin, which may be administered at a reduced dose with indinavir or nelfinavir, is an option; consult
an expert. Exposure to multidrug-resistant tuberculosis may require prophylaxis with two drugs; consult public
health authorities. Possible regimens include pyrazinamide plus either ethambutol or a fluoroquinolone (21 ).
 
§
Protection against Toxoplasma  is provided by the preferred anti-Pneumocystis  regimens. Pyrimethamine alone
probably provides little, if any, protection.
 
¶
Rifabutin should not be administered concurrently with the protease inhibitors saquinavir or ritonavir; however,
it may be administered at half the dose (150 mg q.d.) with indinavir or nelfinavir.
** Vaccination should be offered to persons who have a CD4+ T-lymphocyte count <200 cells/µL, although the
efficacy may be diminished. Some authorities are concerned that immunizations may stimulate the replication
of HIV. However, one study showed no adverse effect of pneumococcal vaccination on patient survival (22 ).
Revaccination ≥5 years after the first dose is considered optional.
 
††
These immunizations or chemoprophylactic regimens do not target pathogens traditionally classified as
opportunistic but should be considered for use in HIV-infected patients. Data are inadequate concerning clinical
benefit of these vaccines in this population, although it is logical to assume that those patients who develop
antibody responses will derive some protection. Some authorities are concerned that immunizations may
stimulate HIV replication, although, for influenza vaccination, a large observational study of HIV-infected persons
in clinical care showed no adverse effect of this vaccine, including multiple doses, on patient survival (J. Ward,
CDC, personal communication). Hepatitis B vaccine has been recommended for all children and adolescents and
for all adults with risk factors for hepatitis B infection (23 ). Rimantadine/amantadine are appropriate during
outbreaks of influenza A. For additional information regarding vaccination against hepatitis B and vaccination
and antiviral therapy against influenza, see references 23 and 24. Because of the theoretical concern that increases
in HIV plasma RNA following vaccination during pregnancy might increase the risk of perinatal transmission of
HIV, providers may wish to defer vaccination until after antiretroviral therapy is initiated.
 
§§




Acyclovir is not protective against CMV. Valaciclovir is not recommended because of an unexplained trend toward
increased mortality observed in persons who have AIDS who were being administered this drug for prevention
of CMV disease.
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TABLE 2B. Prophylaxis for recurrence of opportunistic disease (after chemotherapy










(TMP-SMZ), 1 DS po q.d. (AI);
TMP-SMZ 1 SS po q.d. (AI)
TMP-SMZ, 1 DS po t.i.w.. (CIII);
dapsone, 50 mg po b.i.d. or
100 mg po q.d. (BI); dapsone,
50 mg po q.d. plus
pyrimethamine, 50 mg po q.w.
plus leucovorin, 25 mg po q.w.
(BI); dapsone, 200 mg po plus
pyrimethamine, 75 mg po plus
leucovorin, 25 mg po q.w. (BI);
aerosolized pentamidine, 300 mg






Sulfadiazine 500–1000 mg po
q.i.d. plus pyrimethamine
25–75 mg po q.d. plus
leucovorin 10 mg po q.d. (AI)
Clindamycin, 300–450 mg po q
6-8 h plus pyrimethamine,
25–75 mg po q.d. plus leucovorin,






Clarithromycin, 500 mg po b.i.d.
(AI) plus one or more of the
following: ethambutol,
15 mg/kg po q.d. (AII);
rifabutin, 300 mg po q.d. (AII)
Azithromycin, 500 mg po q.d. (AII)
plus one or more of the following:
ethambutol, 15 mg/kg po q.d.
(AII); rifabutin, 300 mg po q.d. (AII)
Cytomegalovirus Prior end-organ
disease
Ganciclovir, 5–6 mg/kg iv
5–7 days/wk or 1,000 mg po
t.i.d. (AI); or foscarnet,
90–120 mg/kg iv q.d. (AI); or
cidofovir, 5 mg/kg iv q.o.w.
(AI); or (for retinitis)
ganciclovir sustained-release





Fluconazole, 200 mg po q.d. (AI) Amphotericin B, 0.6–1.0 mg/kg iv
q.w.–t.i.w. (AI); itraconazole,





Itraconazole, 200 mg po b.i.d.
(AII)
Amphotericin B, 1.0 mg/kg iv q.w.






Fluconazole, 400 mg po q.d. (AII) Amphotericin B, 1.0 mg/kg iv q.w.





Bacteremia Ciprofloxacin, 500 mg po b.i.d.
for several months (BII)
None





Acyclovir, 200 mg po t.i.d. or






Fluconazole, 100–200 mg po
q.d. (AI)
Ketoconazole, 200 mg po q.d. (CIII);
itraconazole, 200 mg po q.d. (CIII)
     NOTE: Information included in these guidelines may not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms
“safe” and “effective” may not be synonymous with the FDA-defined legal standards for product approval.
DS = double-strength tablet; q.m. = monthly; q.w. = weekly; SS = single-strength tablet; t.i.w. = three times
a week; and TMP-SMZ = trimethoprim-sulfamethoxazole. The Respirgard IITM nebulizer is manufactured by
Marquest, Englewood, CO. Letters and Roman numerals in parentheses after regimens indicate the strength
of the recommendation and the quality of the evidence supporting it (see text).
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*Pyrimethamine/sulfadiazine confers protection against PCP as well as toxoplasmosis; clindamycin-
pyrimethamine does not.
†
Many multiple-drug regimens are poorly tolerated. Drug interactions (e.g., those seen with clarithromycin/
rifabutin) can be problematic; rifabutin has been associated with uveitis, especially when administered at
daily doses of >300 mg or concurrently with fluconazole or clarithromycin. Rifabutin should not be admin-
istered concurrently with the protease inhibitors saquinavir or ritonavir, but it can be administered at half
dose (150 mg q.d.) with indinavir or nelfinavir.
§
The efficacy of eradication of Salmonella  has been demonstrated only for ciprofloxacin.
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in 2 divided doses po t.i.w. on
consecutive days (AII)
Aerosolized pentamidine
(children aged ≥5 yr),
300 mg q.m. via Respirgard
IITM nebulizer (CIII);
dapsone (children aged
≥1 mo), 2 mg/kg (max 100
mg) po q.d. (CIII); iv
pentamidine, 4 mg/kg every
2–4 weeks (CIII)
HIV-infected children aged
1–5 yr with CD4+ count





6–12 yr with CD4+ count
<200/µL or CD4+ percentage
<15%
Single dose po t.i.w. on
consecutive days;
2 divided doses po q.d.;






TST reaction ≥5mm or prior
positive TST result without
treatment or contact with
case of active tuberculosis
Isoniazid 10–15 mg/kg (max 300
mg) po or im q.d. x 12 mo (AI)
or 20–30 mg/kg (max 900 mg)
po b.i.w. x 12 mo (BIII)
Rifampin, 10–20 mg/kg (max




Same as above; high
probability of exposure to
isoniazid-resistant
tuberculosis
Rifampin, 10–20 mg/kg (max







Same as above; high
probability of exposure to
multidrug-resistant
tuberculosis






For children aged ≥6 yrs,
CD4+ count <50/µL; aged
2–6 yrs, CD4+ count <75/µL;
aged 1–2 yrs, CD4+ count
<500/µL; aged <1 yr, CD4+
count <750/µL
Clarithromycin, 7.5 mg/kg (max
500 mg) po b.i.d. (AII), or
azithromycin, 20 mg/kg (max
1,200 mg) po q.w. (AII) 
Children aged ≥6 yrs,
rifabutin, 300 mg po q.d.
(BI); children aged <6 yrs,
5 mg/kg po q.d. when
suspension becomes
available (BI); azithromycin,





varicella with no history of
chickenpox or shingles
Varicella zoster immune
globulin (VZIG), 1 vial
(1.25 mL)/10 kg (max 5 vials)




DRUG REGIMENS FOR CHILDREN
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IgG antibody to Toxoplasma
and severe
immunosuppression
TMP-SMZ, 150/750 mg/m2/d in
2 divided doses po q.d. (BIII)
Dapsone (children aged
≥1 mo), 2 mg/kg or
15 mg/m2 (max 25 mg) po
q.d. plus pyrimethamine,
1 mg/kg po q.d. plus
leucovorin, 5 mg po every
3 days (BIII)
III. Not recommended for most patients; indicated for use only in unusual circumstances
Invasive bacterial
infections**
Hypogammaglobulinemia IVIG (400 mg/kg/q.m.) (AI) None
Candida species Severe immunosuppression Nystatin (100,000 U/mL),
4–6 mL po q 6 h (CIII) or





Severe immunosuppression Fluconazole, 3–6 mg/kg po q.d.
(CII)






Itraconazole, 2–5 mg/kg po 




CMV antibody positivity and
severe immunosuppression
Children aged 6–12 yrs: oral
ganciclovir under investigation
None
     NOTE: Information included in these guidelines may not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms
“safe” and “effective” may not be synonymous with the FDA-defined legal standards for product approval.
b.i.w. = twice a week; CMV = cytomegalovirus; IVIG = intravenous immune globulin; q.m. = monthly; t.i.w. =
three times a week; TMP-SMZ = trimethoprim-sulfamethoxazole; and VZIG = varicella zoster immune
globulin. The Respirgard IITM nebulizer is manufactured by Marquest, Englewood, CO. Letters and Roman
numerals in parentheses after regimens indicate the strength of the recommendation and the quality of the
evidence supporting it (see text).
 * The efficacy of parenteral pentamidine (e.g., 4 mg/kg/month) is controversial. TMP-SMZ, dapsone-
pyrimethamine, and possibly dapsone alone appear to protect against toxoplasmosis, although data have
not been prospectively collected. Daily TMP-SMZ reduces the frequency of some bacterial infections. Patients
receiving therapy for toxoplasmosis with sulfadiazine-pyrimethamine are protected against Pneumocystis
carinii  pneumonia (PCP) and do not need TMP-SMZ.
 
†
Children routinely being administered intravenous immune globulin (IVIG) should receive VZIG if the last
dose of IVIG was administered >21 days before exposure.
 
§
HIV-infected and HIV-exposed children should be immunized according to the following childhood
immunization schedule (Figure), which has been adapted from the January–December 1997 schedule
recommended for immunocompetent children by the Advisory Committee on Immunization Practices, the
American Academy of Pediatrics, and the American Academy of Family Physicians. This schedule differs
from that for immunocompetent children in that IPV replaces OPV, vaccination against S. pneumoniae  (AII)
and influenza (BIII) should be offered, and vaccination against varicella is contraindicated (EIII). MMR should
not be administered to severely immunocompromised children (DIII). Once an HIV-exposed child is
determined not to be HIV infected, the schedule for immunocompetent children applies.
 
¶
Protection against Toxoplasma  is provided by the preferred antipneumocystis regimens. Pyrimethamine
alone probably provides little, if any, protection. For definition of severe immunosuppression, see Table 1.
** Respiratory syncytial virus (RSV) IVIG may be substituted for IVIG during the RSV season.
 
††
Data on oral ganciclovir are still being evaluated; durability of effect is unclear. Acyclovir is not protective
against CMV.






























































Influenza Influenza (a dose is required every year)
Recommendations for these vaccines are the same as those for immunocompetent children
Recommendations for these vaccines differ from those for immunocompetent children
CONTRAINDICATED in all HIV-infected persons
FIGURE. Recommended immunization schedule for HIV-infected children*
     Note: Modified from the immunization schedule for immunocompetent children. This schedule also
applies to children born to HIV-infected mothers whose HIV infection status has not been determined.
Once a child is known not to be HIV-infected, the schedule for immunocompetent children applies. This
schedule indicates the recommended age for routine administration of currently licensed childhood
vaccines. Some combination vaccines are available and may be used whenever administration of all
components of the vaccine is indicated. Providers should consult the manufacturers’ package inserts
for detailed recommendations.
  *Vaccines are listed under the routinely recommended ages. Bars indicate range of acceptable ages for
vaccination. Shaded bars indicate catch-up vaccination: at 11–12 years of age, hepatitis B vaccine should
be administered to children not previously vaccinated. 
† Infants born to HBsAg-negative mothers should receive 2.5 µg of Merck vaccine (Recombivax HB®) or
10 µg of SmithKline Beecham (SB) vaccine (Engerix-B®). The 2nd dose should be administered >1 mo
after the 1st dose.
Infants born to HBsAg-positive mothers should receive 0.5 mL of hepatitis B immune globulin (HBIG)
within 12 hrs of birth and either 5 µg of Merck vaccine (Recombivax HB®) or 10 µg of SB vaccine
(Engerix-B
®
) at a separate site. The 2nd dose is recommended at 1–2 mos of age and the 3rd dose at
6 mos of age.
Infants born to mothers whose HBsAg status is unknown should receive either 5 µg of Merck vaccine
(Recombivax HB®) or 10 µg of SB vaccine (Engerix-B®) within 12 hrs of birth. The 2nd dose of vaccine
is recommended at 1 mo of age and the 3rd dose at 6 mos of age. Blood should be drawn at the time
of delivery to determine the mother’s HBsAg status; if it is positive, the infant should receive HBIG as
soon as possible (no later than 1 wk of age). The dosage and timing of subsequent vaccine doses should
be based upon the mother’s HBsAg status.
§ Children and adolescents who have not been vaccinated against hepatitis B in infancy may begin the
series during any childhood visit. Those who have not previously received 3 doses of hepatitis B vaccine
should initiate or complete the series during the 11- to 12-year–old visit. The 2nd dose should be
administered at least 1 mo after the 1st dose, and the 3rd dose should be administered at least 4 mos
after the 1st dose and at least 2 mos after the 2nd dose. 
¶ DTaP (diphtheria and tetanus toxoids and acellular pertussis vaccine) is the preferred vaccine for all
doses in the vaccination series, including completion of the series in children who have received >1 dose
of whole-cell DTP vaccine. Whole-cell DTP is an acceptable alternative to DTaP. The 4th dose of DTaP
may be administered as early as 12 mos of age, provided 6 mos have elapsed since the 3rd dose, and
if the child is considered unlikely to return at 15–18 mos of age. Td (tetanus and diphtheria toxoids,
adsorbed, for adult use) is recommended at 11–12 yrs of age if at least 5 yrs have elapsed since the
last dose of DTP, DTaP, or DT. Subsequent routine Td boosters are recommended every 10 yrs.
 **Three H. influenzae type b (Hib) conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB®
[Merck]) is administered at 2 and 4 mos of age, a dose at 6 mos is not required. After the primary series
has been completed, any Hib conjugate vaccine may be used as a booster.
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†† Inactivated poliovirus vaccine (IPV) is the only polio vaccine recommended for HIV-infected persons and
their household contacts. Although the third dose of IPV is generally administered at 12–18 months, the
third dose of IPV has been approved to be administered as early as 6 months of age. Oral poliovirus
vaccine (OPV) should NOT be administered to HIV-infected persons or their household contacts.
§§ MMR should not be administered to severely immunocompromised children. HIV-infected children
without severe immunosuppression should routinely receive their first dose of MMR as soon as possible
upon reaching the first birthday. Consideration should be given to administering the second dose of
MMR vaccine as soon as one month (i.e., minimum 28 days) after the first dose, rather than waiting
until school entry.
¶¶ Influenza virus vaccine should be administered to all HIV-infected children >6 months of age each year.
Children aged 6 months–8 years who are receiving influenza vaccine for the first time should receive
two doses of split virus vaccine separated by at least one month. In subsequent years, a single dose of
vaccine (split virus for persons ≤12 years of age, whole or split virus for persons >12 years of age)
should be administered each year. The dose of vaccine for children aged 6–35 months is 0.25 mL; the
dose for children aged ≥3 years is 0.5 mL.
***The 23-valent pneumococcal vaccine should be administered to HIV-infected children at 24 months of
age. Revaccination should generally be offered to HIV-infected children vaccinated 3–5 years (children
aged ≤10 years) or >5 years (children aged >10 years) earlier.
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TABLE 3B. Prophylaxis for recurrence of opportunistic disease (after chemotherapy for




I. Recommended for life as standard of care
Pneumocystis carinii Prior P. carinii
pneumonia
TMP-SMZ, 150/750
mg/m2/d in 2 divided
doses po t.i.w. on
consecutive days (AII)
Aerosolized pentamidine
(children aged ≥5 yrs),
300 mg q.m. via
Respirgard IITM
nebulizer (CIII); dapsone
(children aged ≥1 mo), 2
mg/kg (max 100 mg) po
q.d. (CIII); iv pentam-





Single dose po t.i.w. on
consecutive days;
2 divided doses po q.d.;
2 divided doses po t.i.w.
on alternate days




2–4 divided doses po
q.d. plus
pyrimethamine, 1 mg/kg
or 15 mg/m2 (max
25 mg) po q.d. plus
leucovorin, 5 mg po
every 3 days (AI)
Clindamycin,
20–30 mg/kg/d in
4 divided doses po q.d.
plus pyrimethamine,
1 mg/kg po q.d. plus
leucovorin, 5 mg po
every 3 days (BI)
Mycobacterium avium
complex
Prior disease Clarithromycin, 7.5 mg/kg
(max 500 mg) po b.i.d.
(AII) plus at least one of
the following:
ethambutol, 15 mg/kg
(max 900 mg) po q.d.
(AII); rifabutin, 5 mg/kg




Documented disease Fluconazole, 3–6 mg/kg po
q.d. (AII)
Itraconazole, 2–5 mg/kg




Histoplasma capsulatum Documented disease Itraconazole, 2–5 mg/kg
po q 12–48h (AIII) 
Fluconazole, 3–6 mg/kg po
q.d. (CIII); amphotericin
B, 1.0 mg/kg iv q.w. AIII) 
Coccidioides immitis Documented disease Fluconazole, 6 mg/kg po
q.d. (AIII)
Amphotericin B,
1.0 mg/kg iv q.w. (AII)
Cytomegalovirus Prior end-organ disease Ganciclovir, 5 mg/kg iv
q.d.; or  foscarnet,
90–120 mg/kg iv q.d.






Bacteremia TMP-SMZ, 150/750 mg/m2
in 2 divided doses po
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II. Recommended only if subsequent episodes are frequent or severe
Invasive bacterial
infections§
>2 infections in 1-year
period
TMP-SMZ, 150/750 mg/m2
in 2 divided doses po
q.d. (BI); or IVIG,





Herpes simplex virus Frequent/severe
recurrences
Acyclovir, 80 mg/kg/d in




Fluconazole, 3–6 mg/kg po
q.d. (AII); or
ketoconazole, 5–10
mg/kg po q 24–12h (CIII)
     NOTE: Information included in these guidelines may not represent Food and Drug Administration (FDA)
approval or approved labeling for the particular products or indications in question. Specifically, the terms
“safe” and “effective” may not be synonymous with the FDA-defined legal standards for product approval.
IVIG = intravenous immune globulin; q.m.= monthly; q.w. = weekly; t.i.w. = three times a week; and
TMP-SMZ = trimethoprim-sulfamethoxazole. The Respirgard IITM nebulizer is manufactured by Marquest,
Englewood, CO. Letters and Roman numerals in parentheses after regimens indicate the strength of the
recommendations and the quality of the evidence supporting it (see text).
* Only pyrimethamine plus sulfadiazine confers protection against PCP as well as toxoplasmosis. Although
the clindamycin plus pyrimethamine regimen is the preferred alternative in adults, it has not been tested
in children. However, these drugs are safe and are used for other infections.
†
Drug should be determined by susceptibilities of the organism isolated. Alternatives to TMP-SMZ include
ampicillin, chloramphenicol, or ciprofloxacin. However, ciprofloxacin is not approved for use in persons
aged <18 years; therefore, it should be used in children with caution and only if no alternatives exist.
§
Antimicrobial prophylaxis should be chosen based on the microorganism and antibiotic sensitivities.
TMP-SMZ, if used, should be administered daily. Providers should be cautious about using antibiotics solely
for this purpose because of the potential for development of drug-resistant microorganisms. IVIG may not
provide additional benefit to children receiving daily TMP-SMZ. Choice of antibiotic prophylaxis vs. IVIG
should also involve consideration of adherence, ease of intravenous access, and cost. If IVIG is used, RSV-IVIG
may be substituted for IVIG during the RSV season.
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Sexual Exposures
(1) Patients should use a latex condom during every act of sexual intercourse to re-
duce the risk of acquisition of cytomegalovirus, herpes simplex virus, and human
papillomavirus, as well as other sexually transmitted pathogens (AII). Condom
use also will, theoretically, reduce the risk of acquisition of human herpesvirus 8,
as well as superinfection with an HIV strain that has become resistant to
antiretroviral drugs (BIII) and will prevent transmission of HIV and other sexually
transmitted pathogens to others (AII). Data regarding the use and efficacy of “fe-
male condoms” are incomplete, but these devices should be considered as a risk-
reduction strategy (BIII). 
(2) Patients should avoid sexual practices that may result in oral exposure to feces
(e.g., oral-anal contact) to reduce the risk of intestinal infections (e.g., crypto-
sporidiosis, shigellosis, campylobacteriosis, amebiasis, giardiasis, and hepatitis A
and B) (BIII).
Environmental and Occupational Exposures
(1) Certain activities or types of employment may increase the risk of exposure to
tuberculosis (BIII). These include volunteer work or employment in health-care
facilities, correctional institutions, and shelters for the homeless, as well as other
settings identified as high risk by local health authorities. Decisions about
whether to continue with such activities should be made in conjunction with the
health-care provider and should be based on such factors as the patient’s specific
duties in the workplace, the prevalence of tuberculosis in the community, and the
degree to which precautions designed to prevent the transmission of tuberculosis
are taken in the workplace (BIII). These decisions will affect the frequency with
which the patient should be screened for tuberculosis. 
(2) Child care providers and parents of children in child care are at increased risk of
acquiring CMV infection, cryptosporidiosis, and other infections (e.g., hepatitis A
and giardiasis) from children. The risk of acquiring infection can be diminished by
good hygienic practices, such as hand washing after fecal contact (e.g., during
diaper changing and after contact with urine or saliva) (AII). All children in child
care facilities also are at increased risk of acquiring these same infections; parents
and other caretakers of HIV-infected children should be advised of this risk (BIII). 
(3) Occupations involving contact with animals (e.g., veterinary work and employ-
ment in pet stores, farms, or slaughterhouses) may pose a risk of crypto-
sporidiosis, toxoplasmosis, salmonellosis, campylobacteriosis, or Bartonella
infection. However, the available data are insufficient to justify a recommendation
against work in such settings.
TABLE 4. Advising patients concerning prevention of exposure to opportunistic
pathogens
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(4) Contact with young farm animals, especially animals with diarrhea, should be
avoided to reduce the risk of cryptosporidiosis (BII). 
(5) Hand washing after gardening or other contact with soil may reduce the risk of
cryptosporidiosis and toxoplasmosis (BIII).
(6) In areas endemic for histoplasmosis, patients should avoid activities known to be
associated with increased risk, including cleaning chicken coops, disturbing soil
beneath bird-roosting sites, and exploring caves (CIII). 
(7) In areas endemic for coccidioidomycosis, when possible, patients should avoid
activities associated with increased risk, including those involving extensive ex-
posure to disturbed native soil (e.g., at excavation sites or during dust storms)
(CIII).
Pet-Related Exposures
Health-care providers should advise HIV-infected persons of the potential risk
posed by pet ownership. However, they should be sensitive to the possible psycho-
logical benefits of pet ownership and should not routinely advise HIV-infected persons
to part with their pets (DIII). Specifically, providers should advise HIV-infected patients
of the following.
General
(1) Veterinary care should be sought when a pet develops diarrheal illness. If possi-
ble, HIV-infected persons should avoid contact with animals that have diarrhea
(BIII). A fecal sample should be obtained from animals with diarrhea and exam-
ined for Cryptosporidium, Salmonella, and Campylobacter. 
(2) When obtaining a new pet, HIV-infected patients should avoid animals aged <6
months, especially those with diarrhea (BIII). Because the hygienic and sanitary
conditions in pet-breeding facilities, pet stores, and animal shelters are highly
variable, the patient should be cautious when obtaining a pet from these sources.
Stray animals should be avoided. Animals aged <6 months, especially those with
diarrhea, should be examined by a veterinarian for Cryptosporidium, Salmonella,
and Campylobacter (BIII). 
(3) Patients should wash their hands after handling pets (especially before eating)
and avoid contact with pets’ feces to reduce the risk of cryptosporidiosis, sal-
monellosis, and campylobacteriosis (BIII). Hand washing for HIV-infected children
should be supervised. 
Cats
(4) Patients should consider the potential risks of cat ownership because of the risks
of toxoplasmosis and Bartonella infection, as well as enteric infections (CIII).
Those who elect to obtain a cat should adopt or purchase an animal that is aged
>1 year and in good health to reduce the risk of cryptosporidiosis, Bartonella in-
fection, salmonellosis, and campylobacteriosis (BII).
(5) Litter boxes should be cleaned daily, preferably by an HIV-negative, nonpregnant
person; if the HIV-infected patient performs this task, he or she should wash
hands thoroughly afterward to reduce the risk of toxoplasmosis (BIII). 
TABLE 4. Advising patients concerning prevention of exposure to opportunistic
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(6) To reduce the risk of toxoplasmosis, cats should be kept indoors, should not be
allowed to hunt, and should not be fed raw or undercooked meat (BIII).
(7) Although declawing is not generally advised, patients should avoid activities that
may result in cat scratches or bites to reduce the risk of Bartonella infection (BII).
Patients should also wash sites of cat scratches or bites promptly (CIII) and should
not allow cats to lick open cuts or wounds (BIII).
(8) Care of cats should include flea control to reduce the risk of Bartonella infection
(CIII).
(9) Testing cats for toxoplasmosis (EII) or Bartonella infection (DII) is not
recommended.
Birds
(10) Screening healthy birds for Cryptococcus neoformans, Mycobacterium avium, or
Histoplasma capsulatum is not recommended (DIII).
Other
(11) Contact with reptiles (e.g., snakes, lizards, iguanas, and turtles) should be avoided
to reduce the risk of salmonellosis (BIII).
(12) Gloves should be used during the cleaning of aquariums to reduce the risk of
infection with Mycobacterium marinum (BIII).
(13) Contact with exotic pets (e.g., nonhuman primates) should be avoided (CIII).
Food- and Water-Related Exposures 
(1) Raw or undercooked eggs (including foods that may contain raw eggs [e.g., some
preparations of hollandaise sauce, Caesar and certain other salad dressings, and
mayonnaise]); raw or undercooked poultry, meat, seafood; and unpasteurized
dairy products may contain enteric pathogens. Poultry and meat should be
cooked until no longer pink in the middle (internal temperature, >165 F [73.8 C]).
Produce should be washed thoroughly before being eaten (BIII). 
(2) Cross-contamination of foods should be avoided. Uncooked meats should not be
allowed to come in contact with other foods; hands, cutting boards, counters, and
knives and other utensils should be washed thoroughly after contact with un-
cooked foods (BIII).
(3) Although the incidence of listeriosis is low, it is a serious disease that occurs un-
usually frequently among HIV-infected persons who are severely immunosup-
pressed. Some soft cheeses and some ready-to-eat foods (e.g., hot dogs and cold
cuts from delicatessen counters) have been known to cause listeriosis. An HIV-
infected person who is severely immunosuppressed and who wishes to reduce
the risk of foodborne disease can prevent listeriosis by reheating these foods until
they are steaming before eating them (CIII).
(4) Patients should not drink water directly from lakes or rivers because of the risk of
cryptosporidiosis and giardiasis (AIII). Waterborne infection may also result from
swallowing water during recreational activities. Patients should avoid swimming
in water that is likely to be contaminated with human or animal waste and should
avoid swallowing water during swimming (BII). 
TABLE 4. Advising patients concerning prevention of exposure to opportunistic
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(5) During outbreaks or in other situations in which a community “boil water advi-
sory” is issued, boiling water for 1 minute will eliminate the risk of acquiring cryp-
tosporidiosis (AI). Using submicron, personal-use water filters (home/ office
types) and/or drinking bottled water* may reduce the risk (CIII). Current data are
inadequate to support a recommendation that all HIV-infected persons boil or oth-
erwise avoid drinking tap water in nonoutbreak settings. However, persons who
wish to take independent action to reduce their risk of waterborne crypto-
sporidiosis may choose to take precautions similar to those recommended during
outbreaks. Such decisions are best made in conjunction with a health-care
provider. Persons who opt for a personal-use filter or bottled water should be
aware of the complexities involved in selecting the appropriate products, the lack
of enforceable standards for destruction or removal of oocysts, the cost of the
products, and the difficulty of using these products consistently. Patients taking
precautions to avoid acquiring cryptosporidiosis from drinking water should be
advised that ice made from contaminated tap water also can be a source of infec-
tion (BII). Such persons should be aware that fountain beverages served in restau-
rants, bars, theaters, and other public places may also pose a risk, because these
beverages, as well as the ice they may contain, are made from tap water. Nation-
ally distributed brands of bottled or canned carbonated soft drinks are safe to
drink. Commercially packaged noncarbonated soft drinks and fruit juices that do
not require refrigeration until after they are opened (e.g., those that can be stored
unrefrigerated on grocery shelves) also are safe. Nationally distributed brands of
frozen fruit juice concentrate are safe if they are reconstituted by the user with
water from a safe source. Fruit juices that must be kept refrigerated from the time
they are processed to the time of consumption may be either fresh (unpasteur-
ized) or heat treated (pasteurized); only juices labeled as pasteurized should be
considered free of risk from Cryptosporidium. Other pasteurized beverages and
beers are also considered safe to drink (BII). No data are available concerning
survival of Cryptosporidium oocysts in wine.
Travel-Related Exposures
(1) Travel, particularly to developing countries, may carry significant risks for the ex-
posure of HIV-infected persons to opportunistic pathogens, especially for patients
who are severely immunosuppressed. Consultation with health-care providers
and/or with experts in travel medicine will help patients plan itineraries (BIII).
(2) During travel to developing countries, HIV-infected persons are at even higher risk
for foodborne and waterborne infections than they are in the United States. Foods
and beverages—in particular, raw fruits and vegetables, raw or undercooked sea-
food or meat, tap water, ice made with tap water, unpasteurized milk and dairy
products, and items purchased from street vendors—may be contaminated (AII).
Items that are generally safe include steaming-hot foods, fruits that are peeled by
the traveler, bottled (especially carbonated) beverages, hot coffee or tea, beer,
wine, and water brought to a rolling boil for 1 minute (AII). Treating water with
TABLE 4. Advising patients concerning prevention of exposure to opportunistic
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personal-use filters and bottled water.
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iodine or chlorine may not be as effective as boiling but can be used, perhaps in
conjunction with filtration, when boiling is not practical (BIII).
(3) Waterborne infections may result from swallowing water during recreational ac-
tivities. To reduce the risk of cryptosporidiosis and giardiasis, patients should
avoid swallowing water during swimming and should not swim in water that may
be contaminated (e.g., with sewage or animal waste) (BII). 
(4) Antimicrobial prophylaxis for traveler’s diarrhea is not recommended routinely
for HIV-infected persons traveling to developing countries (DIII). Such preventive
therapy can have adverse effects and can promote the emergence of drug-
resistant organisms. Nonetheless, several studies (none involving an HIV-infected
population) have shown that prophylaxis can reduce the risk of diarrhea among
travelers. Under selected circumstances (e.g., those in which the risk of infection
is very high and the period of travel brief), the provider and patient may weigh the
potential risks and benefits and decide that antibiotic prophylaxis is warranted
(CIII). For those persons to whom prophylaxis is offered, fluoroquinolones (e.g.,
ciprofloxacin [500 mg q.d.]) can be considered (BIII). Trimethoprim-sulfamethoxazole
(TMP-SMZ) (one double-strength tablet daily) also has been shown to be effec-
tive, but resistance to this drug is now common in tropical areas. Persons already
taking TMP-SMZ for prophylaxis against Pneumocystis carinii pneumonia (PCP)
may gain some protection against traveler’s diarrhea. For HIV-infected persons
who are not already taking TMP-SMZ, health-care providers should be cautious in
prescribing this agent for prophylaxis of diarrhea because of the high rates of
adverse reactions and the possible need for the agent for other purposes (e.g.,
PCP prophylaxis) in the future.
(5) All HIV-infected travelers to developing countries should carry a sufficient supply
of an antimicrobial agent to be taken empirically should diarrhea develop (BIII).
One appropriate regimen is 500 mg of ciprofloxacin b.i.d. for 3–7 days. Alternative
antibiotics (e.g., TMP-SMZ) should be considered as empirical therapy for use by
children and pregnant women (CIII). Travelers should consult a physician if their
diarrhea is severe and does not respond to empirical therapy, if their stools con-
tain blood, if fever is accompanied by shaking chills, or if dehydration develops.
Antiperistaltic agents (e.g., diphenoxylate and loperamide) are used for the treat-
ment of diarrhea; however, they should not be used by patients with high fever or
with blood in the stool, and their use should be discontinued if symptoms persist
beyond 48 hours (AII). These drugs are not recommended for children (DIII).
(6) Travelers should be advised about other preventive measures appropriate for an-
ticipated exposures (e.g., chemoprophylaxis for malaria, protection against ar-
thropod vectors, treatment with immune globulin, and vaccination) (AII). They
should avoid direct contact of the skin with soil or sand (e.g., by wearing shoes
and protective clothing and using towels on beaches) in areas where fecal con-
tamination of soil is likely (BIII).
(7) In general, live-virus vaccines should be avoided (EII). An exception is measles
vaccine, which is recommended for nonimmune persons. However, measles
vaccine is not recommended for those who are severely immunosuppressed
(DIII); immune globulin should be considered for measles-susceptible, severely
TABLE 4. Advising patients concerning prevention of exposure to opportunistic
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immunosuppressed persons who are anticipating travel to measles-endemic
countries (BIII). Inactivated (killed) poliovirus vaccine should be used instead of
oral (live) poliovirus vaccine, which is contraindicated for HIV-infected persons.
Persons at risk for exposure to typhoid fever should be administered an inacti-
vated parenteral typhoid vaccine instead of the live attenuated oral preparation.
Yellow fever vaccine is a live-virus vaccine with uncertain safety and efficacy in
HIV-infected persons. Travelers with asymptomatic HIV infection who cannot
avoid potential exposure to yellow fever should be offered the choice of vaccina-
tion. If travel to a zone with yellow fever is necessary and vaccination is not ad-
ministered, patients should be advised of the risk, instructed in methods for
avoiding the bites of vector mosquitoes, and provided with a vaccination waiver
letter.
(8) In general, killed vaccines (e.g., diphtheria-tetanus, rabies, hepatitis A, Japanese
encephalitis vaccines) should be used for HIV-infected persons just as they would
be used for non-HIV-infected persons anticipating travel (BIII). Preparation for
travel should include a review and updating of routine vaccinations, including
diphtheria-tetanus for adults and all routine immunizations for children. The cur-
rently available cholera vaccine is not recommended for persons following a
usual tourist itinerary, even if travel includes countries reporting cases of cholera
(DII).
(9) Travelers should be informed about other area-specific risks and instructed in
ways to reduce those risks (BIII). Geographically focal infections that pose a high
risk to HIV-infected persons include visceral leishmaniasis (a protozoan infection
transmitted by the sandfly) and several fungal infections (e.g., Penicillium marnef-
fei infection, coccidioidomycosis, and histoplasmosis). Many tropical and devel-
oping areas have high rates of tuberculosis.
TABLE 4. Advising patients concerning prevention of exposure to opportunistic
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TABLE 5. Wholesale acquisition cost of agents recommended for prevention of
opportunistic infections in patients who have HIV infection
Opportunistic
Pathogen Drug Dose Annual Cost
Pneumocystis carinii Trimethoprim-sulfamethoxazole 160/800 mg q.d. $60
Dapsone 100 mg q.d. $72
Aerosolized pentamidine 300 mg q.m. $1,185
Mycobacterium 
avium complex
Rifabutin 300 mg q.d. $ 2,916
Clarithromycin 500 mg b.i.d. $ 2,347
Azithromycin 1,200 mg q.w. $1,490
Cytomegalovirus Ganciclovir (iv) 5 mg/kg q.d. $8,891
Foscarnet (iv) 90–120 mg/kg q.d. $27,800–37,200
Ganciclovir (po) 1,000 mg t.i.d. $17,082




Isoniazid 300 mg q.d. $31
Rifampin 600 mg q.d. $1,542
Pyrazinamide 1,500 mg q.d. $1,187
Ethambutol 900 mg q.d. $1,370
Fungi Fluconazole 200 mg q.d. $5,018
Itraconazole 200 mg q.d. $4,239
Ketoconazole 200 mg q.d. $1,069
Herpes simplex virus Acyclovir 400 mg t.i.d. $2,377
Toxoplasma gondii Pyrimethamine 500 mg q.w. $43





pneumoniae 23-valent pneumococcal 0.5 mL im $15
Influenza virus Influenza vaccine 0.5 mL im $5
Hepatitis B virus Recombinant hepatitis B 10–20 µg im x 3 $173
Source: Drug Topics Red Book, Medical Economics Inc., Montvale, NJ, 1997.
COSTS OF DRUGS AND VACCINES
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